湖北众联资产评估有限公司关于深圳证券交易所对爱尔眼
科医院集团股份有限公司重组问询函的回复
深圳证券交易所创业板公司管理部:
爱尔眼科医院集团股份有限公司于2020年1月15日收到《关于对爱尔眼科医院集团股份有限公司的重组问询函》(创业板许可类重组问询函〔2020〕第 4号)。本次问询函涉及评估机构回复相关事项3项,具体回复如下:
问题4:报告书显示,截至2019年9月30日,奥理德视光和宣城眼科医院其他应付款分别为3,235.49万元、2,108.12万元,主要为应付众生药业股利款;而奥理德视光主营业务中,医疗服务收入占比逐渐下降,视光服务收入占比逐渐提升。
(1)请补充披露上述应付股利对奥理德视光和宣城眼科医院评估结果的影响;在奥理德视光和宣城眼科医院转让前进行股利分配的主要原因、合理与合规性,是否符合奥理德视光和宣城眼科医院既定分红政策,股利具体支付安排,资金来源以及对奥理德视光和宣城眼科医院生产经营的影响;
请独立财务顾问、评估师、会计师、律师进行核查并发表明确意见。
回复:经核查,评估机构认为:上述股利分配事项发生在评估基准日2019年9月30日之前,评估机构在评估时已按评估准则要求进行了相应处理,因此上述股利分配事项对奥理德视光和宣城眼科医院的评估结果没有影响。
问题7:报告书显示,万州爱瑞2019年9月末货币资金减少较多的主要原因是当期万州爱瑞分配了一定金额的股利;截至2019年9月30日,万州爱瑞应付职工薪酬241.69万元,而2018年末、2017年末应付职工薪酬分别为143.43万元、154.56万元;近二年及一期应付个人款分别为259.11万元、265.58万元、
259.21万元。
(1)请补充披露万州爱瑞股利支付时间、转让前进行股利分配的主要原因、
合理与合规性,是否符合万州爱瑞既定分红政策以及已付股利对万州爱瑞评估结果的影响;
请独立财务顾问、会计师、评估师核查并发表明确意见。回复:经核查,评估机构认为:上述股利分配事项发生在评估基准日2019年9月30日之前,截至2019年9月30日,上述股利分配已经完成,因此上述股利分配事项对万州爱瑞的评估结果没有影响。
问题24:报告书显示,本次交易所涉标的资产均以收益法作为评估方法,评估增值率在607.22%至2284.46%之间,且收益法与资产基础法预估结果相差较大。
(1)请结合标的门诊量、住院量、手术量、主营业务定价水平变动趋势、近二年及一期实际收入与净利润变动幅度、预计2019年四季度净利润水平等,补充披露收益法预估的未来现金流量增长率、折现率,并量化分析标的公司未来收入增长率测算方法、收入增长来源及可实现性、确定依据及合理性,进一步论证本次评估增值率较高的合理性;
(2)结合收益法和资产基础法评估结果的差异,详细论述估值差异的原因、披露评估方法的选择依据和评估结果的合理性,并就可能存在的资产减值作风险提示。
请独立财务顾问、评估师核查并发表明确意见。
回复:
(一)请结合标的门诊量、住院量、手术量、主营业务定价水平变动趋势、近二年及一期实际收入与净利润变动幅度、预计2019年四季度净利润水平等,补充披露收益法预估的未来现金流量增长率、折现率,并量化分析标的公司未来收入增长率测算方法、收入增长来源及可实现性、确定依据及合理性,进一步论证本次评估增值率较高的合理性;
1、补充披露收益法预估的未来现金流量增长率、折现率
(1)阿迪娅爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,637.99 | 8,710.49 | 10,430.85 | 11,774.02 | 12,656.60 | 13,110.92 | 13,110.92 |
减:营业成本 | 1,108.77 | 5,735.81 | 6,858.72 | 7,737.26 | 8,314.59 | 8,610.26 | 8,604.35 |
税金及附加 | 0.30 | 1.47 | 1.70 | 1.88 | 2.00 | 2.07 | 2.08 |
销售费用 | 172.69 | 618.97 | 733.98 | 809.90 | 848.68 | 876.26 | 884.49 |
管理费用 | 339.16 | 1,431.91 | 1,685.59 | 1,883.81 | 2,014.06 | 2,078.17 | 2,077.80 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:公允价值变动收益 | |||||||
二、营业利润 | 17.07 | 922.33 | 1,150.86 | 1,341.17 | 1,477.27 | 1,544.16 | 1,542.20 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 17.07 | 922.33 | 1,150.86 | 1,341.17 | 1,477.27 | 1,544.16 | 1,542.20 |
减:所得税费用 | 2.56 | 138.35 | 287.72 | 335.29 | 369.32 | 386.04 | 385.55 |
四、净利润 | 14.51 | 783.98 | 863.14 | 1,005.88 | 1,107.95 | 1,158.12 | 1,156.65 |
净利润增长率 | 76.03% | 10.10% | 16.54% | 10.15% | 4.53% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 119.99 | 479.88 | 478.78 | 463.64 | 441.66 | 436.39 | 429.83 |
减:营运资金增加 | -43.17 | 221.25 | 241.90 | 195.03 | 128.04 | 65.75 | - |
减:资本性支出(资本金追加) | - | - | 253.45 | 1,104.29 | 1,035.90 | 323.73 | 394.97 |
五、自由现金流量 | 177.67 | 1,042.61 | 846.57 | 170.20 | 385.67 | 1,205.03 | 1,191.51 |
自由现金流量增长率 | -18.80% | -79.90% | 126.60% | 212.45% | -1.12% | ||
折现率 | 11.41% | 11.41% | 11.41% | 11.41% | 11.41% | 11.41% | 11.41% |
(2)银川爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,468.00 | 6,479.42 | 7,038.90 | 7,534.92 | 7,987.01 | 8,420.24 | 8,420.24 |
减:营业成本 | 810.07 | 3,622.71 | 3,952.47 | 4,276.28 | 4,570.63 | 4,797.25 | 4,849.70 |
营业税金及附加 | 0.19 | 0.83 | 0.89 | 0.95 | 1.00 | 1.05 | 1.05 |
销售费用 | 163.83 | 725.49 | 785.36 | 848.11 | 919.66 | 994.84 | 999.51 |
管理费用 | 154.84 | 687.20 | 764.30 | 842.29 | 917.06 | 993.12 | 996.02 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | 339.07 | 1,443.19 | 1,535.88 | 1,567.29 | 1,578.66 | 1,633.98 | 1,573.96 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | 50.00 | 100.00 | 100.00 | - | - | - | - |
三、利润总额 | 289.07 | 1,343.19 | 1,435.88 | 1,567.29 | 1,578.66 | 1,633.98 | 1,573.96 |
减:所得税费用 | 43.36 | 201.48 | 358.97 | 391.82 | 394.67 | 408.50 | 393.49 |
四、净利润 | 245.71 | 1,141.71 | 1,076.91 | 1,175.47 | 1,183.99 | 1,225.48 | 1,180.47 |
净利润增长率 | 20.39% | -5.68% | 9.15% | 0.72% | 3.50% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 85.10 | 390.38 | 377.49 | 365.24 | 365.24 | 285.11 | 345.13 |
减:营运资金增加 | 140.79 | 54.70 | 48.27 | 52.07 | 50.37 | 57.35 | - |
减:资本性支出(资本金追加) | - | 400.00 | 116.75 | - | - | - | 508.04 |
五、自由现金流量 | 190.02 | 1,077.39 | 1,289.38 | 1,488.64 | 1,498.86 | 1,453.24 | 1,017.56 |
自由现金流量增长率 | 19.68% | 15.45% | 0.69% | -3.04% | -29.98% | ||
折现率 | 11.40% | 11.40% | 11.40% | 11.40% | 11.40% | 11.40% | 11.40% |
(3)西宁爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,466.01 | 6,896.71 | 7,804.05 | 8,558.67 | 9,223.11 | 9,924.57 | 9,924.57 |
减:营业成本 | 1,058.05 | 4,839.21 | 5,364.25 | 5,812.06 | 6,191.82 | 6,513.81 | 6,700.12 |
营业税金及附加 | 0.29 | 1.31 | 1.44 | 1.57 | 1.67 | 1.79 | 1.79 |
销售费用 | 139.84 | 607.13 | 647.04 | 662.57 | 683.34 | 703.32 | 708.25 |
管理费用 | 192.38 | 848.55 | 918.03 | 951.31 | 974.12 | 998.28 | 1,008.09 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 |
二、营业利润 | 75.45 | 600.51 | 873.29 | 1,131.16 | 1,372.16 | 1,707.37 | 1,506.32 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | 400.00 | - | - | - | - | - |
三、利润总额 | 75.45 | 200.51 | 873.29 | 1,131.16 | 1,372.16 | 1,707.37 | 1,506.32 |
减:所得税费用 | - | - | 32.76 | 282.79 | 343.04 | 426.84 | 376.58 |
四、净利润 | 75.45 | 200.51 | 840.53 | 848.37 | 1,029.12 | 1,280.53 | 1,129.74 |
净利润增长率 | -17.77% | 319.20% | 0.93% | 21.31% | 24.43% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 83.43 | 339.72 | 343.69 | 324.25 | 315.14 | 214.94 | 297.85 |
减:营运资金增加 | 32.12 | 76.19 | 65.65 | 32.43 | 41.95 | 66.68 | - |
减:资本性支出(资本金追加) | - | 96.00 | - | 126.35 | - | 1,421.32 | 293.99 |
五、自由现金流量 | 126.76 | 368.04 | 1,118.57 | 1,013.84 | 1,302.31 | 7.47 | 1,133.60 |
自由现金流量增长率 | 203.93% | -9.36% | 28.45% | -99.43% | 15,075.37% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(4)烟台爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,067.74 | 5,454.85 | 6,296.23 | 7,220.77 | 8,182.88 | 9,123.21 | 9,123.21 |
减:营业成本 | 969.45 | 3,466.82 | 3,836.16 | 4,506.51 | 4,797.80 | 5,058.47 | 5,141.55 |
营业税金及附加 | 0.08 | 0.34 | 0.38 | 0.64 | 0.65 | 0.67 | 0.67 |
销售费用 | 205.12 | 928.55 | 1,030.71 | 1,111.76 | 1,177.97 | 1,241.04 | 1,248.71 |
管理费用 | 157.42 | 567.45 | 604.19 | 696.46 | 736.92 | 776.84 | 780.04 |
财务费用 | 9.79 | 31.54 | 2.18 | - | - | - | - |
资产减值损失 | |||||||
信用减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | -274.12 | 460.15 | 822.61 | 905.40 | 1,469.54 | 2,046.19 | 1,952.24 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | -274.12 | 460.15 | 822.61 | 905.40 | 1,469.54 | 2,046.19 | 1,952.24 |
减:所得税费用 | - | - | 5.02 | 226.35 | 367.39 | 511.55 | 488.06 |
四、净利润 | -274.12 | 460.15 | 817.59 | 679.05 | 1,102.15 | 1,534.64 | 1,464.18 |
净利润增长率 | -915.00% | 77.68% | -16.94% | 62.31% | 39.24% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 89.76 | 359.03 | 424.97 | 467.59 | 432.62 | 372.93 | 466.88 |
减:营运资金增加 | 705.90 | -37.06 | 42.81 | -26.48 | 80.88 | 87.37 | - |
减:资本性支出(资本金追加) | - | - | 678.49 | 600.00 | - | - | 631.25 |
加:借入债务 | 900.00 | 100.00 | - | - | - | - | - |
减:偿还债务支出 | - | 900.00 | 100.00 | - | - | - | - |
五、自由现金流量 | 9.74 | 56.24 | 421.26 | 573.12 | 1,453.89 | 1,820.20 | 1,299.81 |
自由现金流量增长率 | 649.04% | 36.05% | 153.68% | 25.20% | -28.59% | ||
折现率 | 11.75% | 11.48% | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% |
(5)玉林爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,130.50 | 4,953.41 | 5,435.95 | 5,915.35 | 6,439.33 | 6,908.75 | 6,908.75 |
减:营业成本 | 552.52 | 2,444.21 | 2,717.85 | 3,011.07 | 3,309.12 | 3,519.26 | 3,602.88 |
税金及附加 | 0.04 | 0.17 | 0.17 | 0.19 | 0.20 | 0.20 | 0.25 |
销售费用 | 114.61 | 503.52 | 546.40 | 588.25 | 650.38 | 705.51 | 702.23 |
管理费用 | 107.23 | 458.24 | 507.80 | 563.26 | 624.31 | 687.32 | 691.72 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | 356.10 | 1,547.27 | 1,663.73 | 1,752.58 | 1,855.32 | 1,996.46 | 1,911.67 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 356.10 | 1,547.27 | 1,663.73 | 1,752.58 | 1,855.32 | 1,996.46 | 1,911.67 |
减:所得税费用 | 32.05 | 139.25 | 415.93 | 438.15 | 463.83 | 499.12 | 477.92 |
四、净利润 | 324.05 | 1,408.02 | 1,247.80 | 1,314.43 | 1,391.49 | 1,497.34 | 1,433.75 |
净利润增长率 | 9.85% | -11.38% | 5.34% | 5.86% | 7.61% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 52.00 | 231.38 | 232.99 | 239.34 | 265.27 | 222.75 | 254.63 |
减:营运资金增加 | 137.41 | 67.11 | 62.34 | 84.08 | 91.73 | 89.45 | - |
减:资本性支出(资本金追加) | - | 178.40 | 52.65 | 183.46 | 232.90 | 914.22 | 248.12 |
五、自由现金流量 | 238.64 | 1,393.89 | 1,365.80 | 1,286.23 | 1,332.13 | 716.42 | 1,440.26 |
自由现金流量增长率 | -2.02% | -5.83% | 3.57% | -46.22% | 101.04% | ||
折现率 | 11.40% | 11.40% | 11.40% | 11.40% | 11.40% | 11.40% | 11.40% |
(6)大连爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,070.54 | 5,463.80 | 6,741.79 | 8,018.23 | 9,078.96 | 9,908.44 | 9,908.44 |
减:营业成本 | 654.11 | 3,110.59 | 3,592.22 | 4,082.53 | 4,512.04 | 4,876.78 | 4,859.50 |
营业税金及附加 | 0.55 | 2.06 | 2.41 | 2.77 | 3.06 | 3.30 | 3.30 |
销售费用 | 278.84 | 1,245.44 | 1,384.24 | 1,530.92 | 1,663.95 | 1,816.84 | 1,821.54 |
管理费用 | 229.19 | 1,039.26 | 1,172.10 | 1,313.15 | 1,453.09 | 1,585.24 | 1,588.01 |
财务费用 | 1.09 | 3.26 | |||||
资产减值损失 | |||||||
信用减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | -93.24 | 63.19 | 590.82 | 1,088.86 | 1,446.82 | 1,626.28 | 1,636.09 |
加:营业外收入 | |||||||
减:营业外支出 | |||||||
三、利润总额 | -93.24 | 63.19 | 590.82 | 1,088.86 | 1,446.82 | 1,626.28 | 1,636.09 |
减:所得税费用 | - | - | - | - | - | 392.56 | 409.02 |
四、净利润 | -93.24 | 63.19 | 590.82 | 1,088.86 | 1,446.82 | 1,233.72 | 1,227.07 |
净利润增长率 | -121.21% | 834.99% | 84.30% | 32.87% | -14.73% |
加:扣税后利息 | |||||||
加:折旧与摊销 | 117.16 | 468.59 | 468.59 | 469.19 | 453.96 | 451.58 | 441.77 |
减:营运资金增加 | 122.58 | 123.14 | 121.85 | 124.90 | 112.02 | 65.27 | - |
减:资本性支出(资本金追加) | - | - | - | 290.89 | - | - | 563.15 |
减:偿还债务支出 | - | 100.00 | - | - | - | - | - |
加:借入债务 | 100.00 | - | - | - | - | - | - |
五、自由现金流量 | 1.34 | 308.64 | 937.56 | 1,142.26 | 1,788.76 | 1,620.03 | 1,105.69 |
自由现金流量增长率 | 203.77% | 21.83% | 56.60% | -9.43% | -31.75% | ||
折现率 | 11.48% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(7)十堰爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 533.74 | 4,272.88 | 4,868.84 | 5,515.72 | 6,149.20 | 6,741.08 | 6,741.08 |
减:营业成本 | 461.68 | 2,415.44 | 2,688.62 | 3,151.84 | 3,402.21 | 3,612.51 | 3,634.83 |
税金及附加 | 0.25 | 2.00 | 2.28 | 2.58 | 2.88 | 3.16 | 3.16 |
销售费用 | 181.00 | 539.08 | 581.23 | 665.22 | 711.64 | 754.86 | 757.99 |
管理费用 | 108.80 | 410.11 | 434.28 | 477.27 | 503.73 | 528.07 | 528.60 |
财务费用 | 4.57 | 13.70 | - | - | - | - | - |
资产减值损失 | |||||||
信用减值损失 | |||||||
加:其他收益 |
二、营业利润 | -222.56 | 892.55 | 1,162.43 | 1,218.81 | 1,528.74 | 1,842.48 | 1,816.50 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | |||||||
三、利润总额 | -222.56 | 892.55 | 1,162.43 | 1,218.81 | 1,528.74 | 1,842.48 | 1,816.50 |
减:所得税费用 | -55.64 | 223.14 | 290.61 | 304.70 | 382.19 | 460.62 | 454.13 |
四、净利润 | -166.92 | 669.41 | 871.82 | 914.11 | 1,146.55 | 1,381.86 | 1,362.37 |
净利润增长率 | 40.13% | 30.24% | 4.85% | 25.43% | 20.52% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 50.03 | 225.08 | 238.96 | 284.56 | 284.43 | 265.32 | 291.30 |
减:营运资金增加 | 287.14 | 7.57 | 31.98 | 42.17 | 36.41 | 36.19 | - |
减:资本性支出(资本金追加) | - | 200.00 | 150.00 | 586.12 | - | 1,078.86 | 267.24 |
加:借入债务 | 420.00 | - | - | - | - | - | - |
减:偿还债务支出 | - | 420.00 | - | - | - | - | - |
五、自由现金流量 | 15.97 | 266.92 | 928.80 | 570.38 | 1,394.57 | 532.13 | 1,386.43 |
自由现金流量增长率 | 247.97% | -38.59% | 144.50% | -61.84% | 160.54% | ||
折现率 | 11.57% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(8)梧州爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,018.48 | 4,396.08 | 4,763.02 | 5,149.09 | 5,575.93 | 5,992.30 | 5,992.30 |
减:营业成本 | 538.11 | 2,328.68 | 2,524.67 | 2,710.14 | 2,912.59 | 3,119.38 | 3,086.83 |
税金及附加 | 0.03 | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 |
销售费用 | 113.05 | 483.80 | 523.51 | 551.26 | 593.04 | 643.61 | 648.82 |
管理费用 | 98.39 | 424.25 | 458.40 | 495.65 | 535.96 | 578.10 | 576.40 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | 268.90 | 1,159.24 | 1,256.32 | 1,391.92 | 1,534.21 | 1,651.08 | 1,680.12 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | 100.00 | 200.00 | 200.00 | 200.00 | - | - | - |
三、利润总额 | 168.90 | 959.24 | 1,056.32 | 1,191.92 | 1,534.21 | 1,651.08 | 1,680.12 |
减:所得税费用 | 15.20 | 86.33 | 264.08 | 297.98 | 383.55 | 412.77 | 420.03 |
四、净利润 | 153.70 | 872.91 | 792.24 | 893.94 | 1,150.66 | 1,238.31 | 1,260.09 |
净利润增长率 | 12.97% | -9.24% | 12.84% | 28.72% | 7.62% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 74.46 | 297.89 | 297.89 | 283.27 | 277.18 | 283.35 | 254.32 |
减:营运资金增加 | 32.39 | 131.62 | 139.12 | 159.14 | 172.07 | 172.10 | - |
减:资本性支出(资本金追加) | - | - | - | 127.37 | - | 1,026.00 | 271.60 |
五、自由现金流量 | 195.77 | 1,039.18 | 951.01 | 890.70 | 1,255.77 | 323.56 | 1,242.81 |
自由现金流量增长率 | -8.48% | -6.34% | 40.99% | -74.23% | 284.10% | ||
折现率 | 11.41% | 11.41% | 11.41% | 11.41% | 11.41% | 11.41% | 11.41% |
(9)上饶爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 497.03 | 3,681.80 | 3,897.33 | 4,158.82 | 4,472.75 | 4,855.71 | 4,855.71 |
减:营业成本 | 433.92 | 2,040.54 | 2,126.64 | 2,246.70 | 2,384.59 | 2,496.54 | 2,534.04 |
税金及附加 | 0.09 | 0.42 | 0.44 | 0.47 | 0.50 | 0.54 | 0.54 |
销售费用 | 75.77 | 466.60 | 487.47 | 503.41 | 537.58 | 578.11 | 581.67 |
管理费用 | 109.27 | 487.53 | 506.82 | 526.90 | 550.96 | 576.08 | 577.47 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:投资收益 | |||||||
二、营业利润 | -122.02 | 686.71 | 775.96 | 881.34 | 999.12 | 1,204.44 | 1,161.99 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | -122.02 | 686.71 | 775.96 | 881.34 | 999.12 | 1,204.44 | 1,161.99 |
减:所得税费用 | -30.51 | 171.68 | 193.99 | 220.34 | 249.78 | 301.11 | 290.50 |
四、净利润 | -91.51 | 515.03 | 581.97 | 661.00 | 749.34 | 903.33 | 871.49 |
净利润增长率 | 37.94% | 13.00% | 13.58% | 13.36% | 20.55% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 87.69 | 358.58 | 337.26 | 321.67 | 321.03 | 267.85 | 310.30 |
减:营运资金增加 | -84.31 | 67.29 | 10.65 | 7.43 | 9.92 | 26.87 | - |
减:资本性支出(资本金追加) | - | - | - | 185.04 | - | - | 459.32 |
五、自由现金流量 | 80.49 | 806.32 | 908.58 | 790.20 | 1,060.45 | 1,144.31 | 722.47 |
自由现金流量增长率 | 12.68% | -13.03% | 34.20% | 7.91% | -36.86% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(10)大同爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 962.64 | 5,000.00 | 6,000.00 | 6,900.00 | 7,600.00 | 7,980.00 | 7,980.00 |
减:营业成本 | 495.31 | 2,537.74 | 3,214.82 | 3,711.56 | 4,109.43 | 4,370.05 | 4,447.42 |
营业税金及附加 | 0.12 | 0.58 | 0.75 | 0.84 | 0.91 | 0.95 | 0.95 |
销售费用 | 73.75 | 386.77 | 480.32 | 561.33 | 637.87 | 705.57 | 709.06 |
管理费用 | 108.09 | 546.89 | 680.44 | 807.21 | 915.19 | 1,016.55 | 1,018.43 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | 285.37 | 1,528.02 | 1,623.67 | 1,819.06 | 1,936.60 | 1,886.88 | 1,804.14 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 285.37 | 1,528.02 | 1,623.67 | 1,819.06 | 1,936.60 | 1,886.88 | 1,804.14 |
减:所得税费用 | 71.34 | 382.01 | 405.92 | 454.77 | 484.15 | 471.72 | 451.04 |
四、净利润 | 214.03 | 1,146.01 | 1,217.75 | 1,364.29 | 1,452.45 | 1,415.16 | 1,353.10 |
净利润增长率 | 32.46% | 6.26% | 12.03% | 6.46% | -2.57% |
加:扣税后利息 | |||||||
加:折旧与摊销 | 48.83 | 195.31 | 322.82 | 308.15 | 308.15 | 263.88 | 331.75 |
减:营运资金增加 | 78.34 | 512.87 | - | - | - | - | - |
减:资本性支出(资本金追加) | - | - | 1,124.87 | - | - | - | 440.79 |
五、自由现金流量 | 184.52 | 828.45 | 415.70 | 1,672.44 | 1,760.60 | 1,679.04 | 1,244.06 |
自由现金流量增长率 | -49.82% | 302.32% | 5.27% | -4.63% | -25.91% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(11)江门爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 947.42 | 5,391.75 | 6,679.07 | 7,500.70 | 7,943.24 | 8,171.01 | 8,171.01 |
减:营业成本 | 732.10 | 3,294.72 | 4,085.58 | 4,589.44 | 4,864.92 | 5,002.36 | 4,983.46 |
税金及附加 | 0.11 | 0.55 | 0.69 | 0.78 | 0.82 | 0.85 | 0.85 |
销售费用 | 90.47 | 682.81 | 838.04 | 931.08 | 972.69 | 993.99 | 995.99 |
管理费用 | 111.03 | 799.82 | 974.74 | 1,083.85 | 1,139.06 | 1,160.94 | 1,159.91 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
二、营业利润 | 13.71 | 613.85 | 780.02 | 895.55 | 965.75 | 1,012.87 | 1,030.80 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 13.71 | 613.85 | 780.02 | 895.55 | 965.75 | 1,012.87 | 1,030.80 |
减:所得税费用 | - | 103.32 | 195.01 | 223.89 | 241.44 | 253.22 | 257.70 |
四、净利润 | 13.71 | 510.53 | 585.01 | 671.66 | 724.31 | 759.65 | 773.10 |
净利润增长率 | 24.54% | 14.59% | 14.81% | 7.84% | 4.88% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 82.95 | 331.74 | 331.74 | 328.80 | 321.13 | 316.42 | 297.08 |
减:营运资金增加 | 63.98 | 40.80 | 63.09 | 50.78 | 28.88 | 15.37 | - |
减:资本性支出(资本金追加) | - | - | - | 174.76 | - | - | 396.01 |
五、自由现金流量 | 32.68 | 801.47 | 853.66 | 774.92 | 1,016.56 | 1,060.70 | 674.17 |
自由现金流量增长率 | 6.51% | -9.22% | 31.18% | 4.34% | -36.44% | ||
折现率 | 11.42% | 11.42% | 11.42% | 11.42% | 11.42% | 11.42% | 11.42% |
(12)临汾爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 565.70 | 3,974.33 | 4,816.02 | 5,597.87 | 6,157.03 | 6,465.18 | 6,465.18 |
减:营业成本 | 441.60 | 2,440.19 | 2,934.14 | 3,344.41 | 3,689.55 | 3,887.79 | 3,828.38 |
营业税金及附加 | 0.13 | 0.54 | 0.63 | 0.71 | 0.77 | 0.81 | 0.81 |
销售费用 | 135.75 | 550.10 | 602.94 | 656.12 | 685.85 | 719.09 | 722.42 |
管理费用 | 98.93 | 567.56 | 645.45 | 724.35 | 795.83 | 858.54 | 857.48 |
财务费用 | 1.20 | 3.59 | - | - | - | - | - |
资产减值损失 |
信用减值损失 | |||||||
二、营业利润 | -111.91 | 412.35 | 632.86 | 872.28 | 985.03 | 998.95 | 1,056.09 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | -111.91 | 412.35 | 632.86 | 872.28 | 985.03 | 998.95 | 1,056.09 |
减:所得税费用 | - | 80.52 | 158.22 | 218.07 | 246.26 | 249.74 | 264.02 |
四、净利润 | -111.91 | 331.83 | 474.64 | 654.21 | 738.77 | 749.21 | 792.07 |
净利润增长率 | 227.70% | 43.04% | 37.83% | 12.93% | 1.41% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 75.55 | 327.17 | 371.42 | 371.44 | 359.00 | 355.72 | 295.70 |
减:营运资金增加 | 13.11 | 208.70 | - | - | - | - | - |
减:资本性支出(资本金追加) | 50.04 | 200.00 | 354.00 | 61.39 | - | - | 370.05 |
减:偿还债务支出 | - | 110.00 | - | - | - | - | - |
加:借入债务 | 110.00 | - | - | - | - | - | - |
五、自由现金流量 | 10.49 | 140.30 | 492.06 | 964.26 | 1,097.77 | 1,104.93 | 717.72 |
自由现金流量增长率 | 250.72% | 95.96% | 13.85% | 0.65% | -35.04% | ||
折现率 | 11.49% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(13)东营爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 852.19 | 4,056.08 | 4,767.78 | 5,492.18 | 6,217.76 | 6,820.53 | 6,820.53 |
减:营业成本 | 549.11 | 2,501.82 | 2,852.73 | 3,218.89 | 3,704.97 | 4,040.87 | 4,046.16 |
营业税金及附加 | 0.19 | 0.79 | 0.90 | 1.01 | 1.17 | 1.27 | 1.27 |
销售费用 | 114.25 | 477.96 | 531.34 | 584.76 | 650.25 | 704.58 | 711.09 |
管理费用 | 151.15 | 628.95 | 684.59 | 742.99 | 803.72 | 862.25 | 899.08 |
财务费用 | 2.72 | 8.16 | - | - | - | - | - |
资产减值损失 | |||||||
信用减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | 34.77 | 438.40 | 698.22 | 944.53 | 1,057.65 | 1,211.56 | 1,162.93 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 34.77 | 438.40 | 698.22 | 944.53 | 1,057.65 | 1,211.56 | 1,162.93 |
减:所得税费用 | - | - | - | 204.04 | 264.41 | 302.89 | 290.73 |
四、净利润 | 34.77 | 438.40 | 698.22 | 740.49 | 793.24 | 908.67 | 872.20 |
净利润增长率 | 147.70% | 59.27% | 6.05% | 7.12% | 14.55% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 69.08 | 276.33 | 264.50 | 250.93 | 346.23 | 355.95 | 349.15 |
减:营运资金增加 | 332.39 | 33.37 | 34.02 | -16.13 | -4.84 | 13.73 | - |
减:资本性支出(资本金追加) | - | - | - | 179.83 | 750.00 | 1,136.69 | 331.46 |
加:借入债务 | 250.00 | - | - | - | - | - | - |
减:偿还债务支出 | - | 250.00 | - | - | - | - | - |
五、自由现金流量 | 21.46 | 431.36 | 928.70 | 827.72 | 394.31 | 114.20 | 889.89 |
自由现金流量增长率 | 115.30% | -10.87% | -52.36% | -71.04% | 679.24% |
折现率 | 11.58% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% |
(14)德州爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 505.09 | 3,573.47 | 4,166.47 | 4,747.67 | 5,313.65 | 5,860.02 | 5,860.02 |
减:营业成本 | 467.22 | 2,551.20 | 2,846.92 | 3,083.65 | 3,312.89 | 3,286.32 | 3,568.69 |
营业税金及附加 | 0.12 | 0.62 | 0.72 | 0.77 | 0.82 | 0.90 | 0.90 |
销售费用 | 97.49 | 533.76 | 583.86 | 596.32 | 628.24 | 655.52 | 666.37 |
管理费用 | 77.21 | 405.41 | 437.55 | 468.31 | 498.49 | 523.10 | 526.00 |
财务费用 | 1.31 | 3.92 | - | - | - | - | - |
资产减值损失 | |||||||
信用减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | -138.26 | 78.56 | 297.42 | 598.62 | 873.21 | 1,394.18 | 1,098.06 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | -138.26 | 78.56 | 297.42 | 598.62 | 873.21 | 1,394.18 | 1,098.06 |
减:所得税费用 | - | - | 72.62 | 149.66 | 218.30 | 348.55 | 274.52 |
四、净利润 | -138.26 | 78.56 | 224.80 | 448.96 | 654.91 | 1,045.63 | 823.54 |
净利润增长率 | -566.88% | 278.58% | 101.27% | 45.87% | 59.66% | ||
加:扣税后利息 |
加:折旧与摊销 | 114.61 | 613.54 | 632.40 | 610.64 | 606.70 | 329.53 | 570.17 |
减:营运资金增加 | 86.25 | 85.68 | 26.48 | 25.79 | 25.77 | 61.38 | - |
减:资本性支出(资本金追加) | - | 415.46 | 357.70 | - | - | 325.01 | 767.25 |
加:借入债务 | 120.00 | - | - | - | - | - | - |
减:偿还债务支出 | - | 120.00 | - | - | - | - | - |
五、自由现金流量 | 10.10 | 70.96 | 473.02 | 1,033.81 | 1,235.84 | 988.77 | 626.46 |
自由现金流量增长率 | 566.60% | 118.56% | 19.54% | -19.99% | -36.64% | ||
折现率 | 11.46% | 11.39% | 11.39% | 11.39% | 11.39% | 11.39% | 11.39% |
(15)仙桃爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 612.81 | 3,410.37 | 3,711.20 | 4,001.75 | 4,247.69 | 4,465.65 | 4,465.65 |
减:营业成本 | 374.05 | 1,921.56 | 2,075.54 | 2,229.07 | 2,365.93 | 2,476.33 | 2,507.67 |
税金及附加 | 0.02 | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.12 |
销售费用 | 51.67 | 273.86 | 292.62 | 306.28 | 325.98 | 344.17 | 347.70 |
管理费用 | 64.63 | 295.89 | 311.21 | 326.57 | 340.45 | 352.62 | 353.32 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
二、营业利润 | 122.44 | 918.96 | 1,031.72 | 1,139.72 | 1,215.22 | 1,292.41 | 1,256.84 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 122.44 | 918.96 | 1,031.72 | 1,139.72 | 1,215.22 | 1,292.41 | 1,256.84 |
减:所得税费用 | 30.61 | 229.74 | 257.93 | 284.93 | 303.81 | 323.10 | 314.21 |
四、净利润 | 91.83 | 689.22 | 773.79 | 854.79 | 911.41 | 969.31 | 942.63 |
净利润增长率 | 27.47% | 12.27% | 10.47% | 6.62% | 6.35% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 51.26 | 205.07 | 208.06 | 198.81 | 191.51 | 166.37 | 201.94 |
减:营运资金增加 | -30.88 | 66.28 | 22.50 | 21.36 | 18.71 | 19.30 | - |
减:资本性支出(资本金追加) | - | - | 56.00 | 79.96 | - | 1,015.88 | 191.76 |
五、自由现金流量 | 173.97 | 828.01 | 903.35 | 952.28 | 1,084.21 | 100.50 | 952.81 |
自由现金流量增长率 | 9.10% | 5.42% | 13.85% | -90.73% | 848.07% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(16)中山爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 822.53 | 3,974.46 | 4,739.12 | 5,541.67 | 6,276.73 | 6,881.81 | 6,881.81 |
减:营业成本 | 521.13 | 2,502.24 | 2,939.16 | 3,282.58 | 3,613.99 | 3,898.70 | 3,907.39 |
税金及附加 | 0.06 | 0.26 | 0.27 | 0.29 | 0.31 | 0.32 | 0.35 |
销售费用 | 118.12 | 524.58 | 610.87 | 695.12 | 773.12 | 847.02 | 849.82 |
管理费用 | 92.23 | 412.08 | 468.23 | 529.77 | 588.76 | 645.99 | 646.12 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:资产处置收益 | |||||||
二、营业利润 | 90.99 | 535.30 | 720.59 | 1,033.91 | 1,300.55 | 1,489.78 | 1,478.13 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 90.99 | 535.30 | 720.59 | 1,033.91 | 1,300.55 | 1,489.78 | 1,478.13 |
减:所得税费用 | - | - | 115.50 | 258.48 | 325.14 | 372.45 | 369.53 |
四、净利润 | 90.99 | 535.30 | 605.09 | 775.43 | 975.41 | 1,117.33 | 1,108.60 |
净利润增长率 | 65.40% | 13.04% | 28.15% | 25.79% | 14.55% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 84.05 | 346.69 | 365.44 | 355.63 | 347.25 | 347.25 | 328.96 |
减:营运资金增加 | 34.93 | 58.04 | 59.26 | 55.01 | 57.75 | 49.82 | - |
减:资本性支出(资本金追加) | - | 84.00 | 150.00 | 99.59 | - | - | 453.17 |
五、自由现金流量 | 140.11 | 739.95 | 761.27 | 976.46 | 1,264.91 | 1,414.76 | 984.39 |
自由现金流量增长率 | 2.88% | 28.27% | 29.54% | 11.85% | -30.42% | ||
折现率 | 11.42% | 11.42% | 11.42% | 11.42% | 11.42% | 11.42% | 11.42% |
(17)钦州爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 732.89 | 3,469.65 | 4,049.89 | 4,643.43 | 5,196.36 | 5,571.95 | 5,571.95 |
减:营业成本 | 386.33 | 1,789.46 | 2,121.58 | 2,434.77 | 2,659.38 | 2,781.43 | 2,875.28 |
税金及附加 | 0.03 | 0.11 | 0.16 | 0.16 | 0.17 | 0.17 | 0.17 |
销售费用 | 110.41 | 488.51 | 583.49 | 643.75 | 705.45 | 758.36 | 762.19 |
管理费用 | 110.34 | 471.37 | 544.46 | 604.18 | 653.75 | 698.04 | 702.62 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | 125.78 | 720.20 | 800.20 | 960.57 | 1,177.61 | 1,333.95 | 1,231.69 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 125.78 | 720.20 | 800.20 | 960.57 | 1,177.61 | 1,333.95 | 1,231.69 |
减:所得税费用 | 11.32 | 64.82 | 200.05 | 240.14 | 294.40 | 333.49 | 307.92 |
四、净利润 | 114.46 | 655.38 | 600.15 | 720.43 | 883.21 | 1,000.46 | 923.77 |
净利润增长率 | 28.00% | -8.43% | 20.04% | 22.59% | 13.28% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 52.58 | 219.09 | 262.12 | 319.63 | 319.08 | 274.17 | 313.66 |
减:营运资金增加 | 144.58 | 38.58 | 47.14 | 46.73 | 46.37 | 38.19 | - |
减:资本性支出(资本金追加) | - | 70.00 | 437.53 | 595.00 | - | - | 399.88 |
五、自由现金流量 | 22.46 | 765.89 | 377.60 | 398.33 | 1,155.92 | 1,236.44 | 837.55 |
自由现金流量增长率 | -50.70% | 5.49% | 190.19% | 6.97% | -32.26% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(18)延吉爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 564.34 | 3,401.41 | 4,027.50 | 4,672.81 | 5,157.52 | 5,471.07 | 5,471.07 |
减:营业成本 | 301.71 | 1,821.67 | 2,156.94 | 2,504.40 | 2,766.77 | 2,936.13 | 2,948.31 |
税金及附加 | 0.07 | 0.42 | 0.49 | 0.56 | 0.62 | 0.65 | 0.65 |
销售费用 | 77.89 | 484.22 | 561.86 | 651.87 | 719.46 | 763.22 | 765.91 |
管理费用 | 75.92 | 490.32 | 574.28 | 663.23 | 730.24 | 771.03 | 772.98 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
二、营业利润 | 108.75 | 604.78 | 733.93 | 852.75 | 940.43 | 1,000.04 | 983.22 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 108.75 | 604.78 | 733.93 | 852.75 | 940.43 | 1,000.04 | 983.22 |
减:所得税费用 | 27.19 | 151.20 | 183.48 | 213.19 | 235.11 | 250.01 | 245.81 |
四、净利润 | 81.56 | 453.58 | 550.45 | 639.56 | 705.32 | 750.03 | 737.41 |
净利润增长率 | 17.21% | 21.36% | 16.19% | 10.28% | 6.34% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 49.05 | 195.54 | 183.20 | 182.90 | 182.90 | 131.47 | 188.29 |
减:营运资金增加 | -67.14 | 80.78 | 22.07 | 23.75 | 17.41 | 19.77 | - |
减:资本性支出(资本金追加) | - | - | 36.46 | - | - | - | 282.09 |
五、自由现金流量 | 197.75 | 568.34 | 675.12 | 798.71 | 870.81 | 861.73 | 643.61 |
自由现金流量增长率 | 18.79% | 18.31% | 9.03% | -1.04% | -25.31% | ||
折现率 | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% |
(19)柳州爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 713.84 | 3,239.98 | 3,742.71 | 4,271.52 | 4,720.12 | 5,109.73 | 5,109.73 |
减:营业成本 | 427.37 | 1,919.33 | 2,179.42 | 2,464.23 | 2,730.73 | 2,968.21 | 2,983.96 |
税金及附加 | 0.06 | 0.24 | 0.24 | 0.26 | 0.27 | 0.27 | 0.29 |
销售费用 | 104.00 | 507.42 | 562.35 | 606.83 | 655.58 | 704.25 | 707.69 |
管理费用 | 91.70 | 391.58 | 427.76 | 467.21 | 503.03 | 537.49 | 538.08 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | 90.71 | 421.41 | 572.94 | 732.99 | 830.51 | 899.51 | 879.71 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 90.71 | 421.41 | 572.94 | 732.99 | 830.51 | 899.51 | 879.71 |
减:所得税费用 | - | - | 131.90 | 183.25 | 207.63 | 224.88 | 219.93 |
四、净利润 | 90.71 | 421.41 | 441.04 | 549.74 | 622.88 | 674.63 | 659.78 |
净利润增长率 | 120.01% | 4.66% | 24.65% | 13.30% | 8.31% |
加:扣税后利息 | |||||||
加:折旧与摊销 | 62.20 | 248.74 | 254.37 | 246.50 | 243.10 | 235.61 | 234.88 |
减:营运资金增加 | 141.39 | 5.54 | -7.30 | -0.91 | -0.62 | -0.25 | - |
减:资本性支出(资本金追加) | - | - | 45.00 | 178.39 | - | - | 315.53 |
五、自由现金流量 | 11.52 | 664.61 | 657.71 | 618.76 | 866.60 | 910.49 | 579.13 |
自由现金流量增长率 | -1.04% | -5.92% | 40.05% | 5.06% | -36.39% | ||
折现率 | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% |
(20)安庆爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 556.94 | 2,909.34 | 3,331.04 | 3,744.27 | 4,088.32 | 4,376.31 | 4,376.31 |
减:营业成本 | 421.14 | 1,694.21 | 1,878.42 | 2,068.06 | 2,227.65 | 2,341.52 | 2,380.79 |
税金及附加 | 0.48 | 2.44 | 2.78 | 3.12 | 3.40 | 3.64 | 3.64 |
销售费用 | 94.69 | 352.24 | 389.51 | 419.89 | 444.18 | 472.32 | 476.30 |
管理费用 | 123.75 | 453.70 | 491.76 | 531.22 | 566.63 | 597.92 | 599.95 |
财务费用 | 1.41 | 4.24 | |||||
信用减值损失 | |||||||
资产减值损失 | |||||||
加:资产处置收益 | |||||||
其他收益 | |||||||
二、营业利润 | -84.53 | 402.51 | 568.57 | 721.98 | 846.46 | 960.91 | 915.63 |
加:营业外收入 | |||||||
减:营业外支出 | 70.00 | 70.00 | |||||
三、利润总额 | -84.53 | 332.51 | 498.57 | 721.98 | 846.46 | 960.91 | 915.63 |
减:所得税费用 | -21.13 | 83.13 | 124.64 | 180.50 | 211.62 | 240.23 | 228.91 |
四、净利润 | -63.40 | 249.38 | 373.93 | 541.48 | 634.84 | 720.68 | 686.72 |
净利润增长率 | 121.12% | 49.94% | 44.81% | 17.24% | 13.52% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 45.94 | 181.44 | 181.44 | 173.11 | 165.89 | 151.21 | 184.78 |
减:营运资金增加 | 90.06 | 14.59 | 47.92 | 46.24 | 39.24 | 36.97 | - |
减:资本性支出(资本金追加) | 8.80 | - | - | 72.71 | - | - | 247.13 |
减:偿还债务支出 | - | 130.00 | - | - | - | - | - |
加:借入债务 | 130.00 | - | - | - | - | - | - |
五、自由现金流量 | 13.68 | 286.23 | 507.45 | 595.64 | 761.49 | 834.92 | 624.37 |
自由现金流量增长率 | 77.29% | 17.38% | 27.84% | 9.64% | -25.22% | ||
折现率 | 11.54% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% |
(21)玉溪爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 385.56 | 2,821.45 | 3,364.49 | 3,897.47 | 4,417.53 | 4,856.86 | 4,856.86 |
减:营业成本 | 359.04 | 2,036.09 | 2,298.83 | 2,566.04 | 2,822.02 | 3,005.09 | 3,036.98 |
税金及附加 | 0.04 | 0.17 | 0.18 | 0.19 | 0.19 | 0.20 | 0.20 |
销售费用 | 69.71 | 393.61 | 441.89 | 482.85 | 521.57 | 566.90 | 570.92 |
管理费用 | 72.92 | 375.42 | 414.21 | 454.11 | 493.16 | 526.93 | 528.23 |
财务费用 | - | 2.83 | 2.83 | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | -116.15 | 13.33 | 206.55 | 394.28 | 580.59 | 757.74 | 720.53 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | -116.15 | 13.33 | 206.55 | 394.28 | 580.59 | 757.74 | 720.53 |
减:所得税费用 | - | - | - | 35.64 | 145.15 | 189.44 | 180.13 |
四、净利润 | -116.15 | 13.33 | 206.55 | 358.64 | 435.44 | 568.30 | 540.40 |
净利润增长率 | -111.12% | 1,449.51% | 73.63% | 21.41% | 30.51% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 63.56 | 254.25 | 254.25 | 247.03 | 236.56 | 186.76 | 222.63 |
减:营运资金增加 | -110.57 | 384.31 | - | - | - | - | - |
减:资本性支出(资本金追加) | - | - | - | 91.04 | - | - | 326.46 |
减:偿还债务支出 | - | - | 130.00 | - | |||
加:借入债务 | - | 130.00 | - | ||||
五、自由现金流量 | 57.98 | 13.27 | 330.80 | 514.63 | 672.00 | 755.06 | 436.57 |
自由现金流量增长率 | 2,392.84% | 55.57% | 30.58% | 12.36% | -42.18% | ||
折现率 | 11.44% | 11.55% | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% |
(22)铜陵爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 629.68 | 2,770.61 | 3,003.87 | 3,242.77 | 3,463.74 | 3,647.28 | 3,647.28 |
减:营业成本 | 330.21 | 1,468.41 | 1,570.27 | 1,688.27 | 1,799.81 | 1,884.46 | 1,901.11 |
税金及附加 | 0.07 | 0.36 | 0.38 | 0.41 | 0.43 | 0.45 | 0.45 |
销售费用 | 56.80 | 248.95 | 271.56 | 277.77 | 298.63 | 318.50 | 321.19 |
管理费用 | 69.89 | 293.90 | 316.21 | 341.32 | 369.03 | 397.46 | 398.13 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:投资收益 | |||||||
二、营业利润 | 172.71 | 758.99 | 845.45 | 935.00 | 995.84 | 1,046.41 | 1,026.40 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 172.71 | 758.99 | 845.45 | 935.00 | 995.84 | 1,046.41 | 1,026.40 |
减:所得税费用 | 43.18 | 189.75 | 211.36 | 233.75 | 248.96 | 261.60 | 257.44 |
四、净利润 | 129.53 | 569.24 | 634.09 | 701.25 | 746.88 | 784.81 | 768.96 |
净利润增长率 | 13.49% | 11.39% | 10.59% | 6.51% | 5.08% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 49.71 | 197.41 | 195.29 | 180.04 | 180.04 | 159.62 | 179.40 |
减:营运资金增加 | 82.61 | 27.27 | 20.59 | 21.33 | 20.49 | 19.50 | - |
减:资本性支出(资本金追加) | - | - | 70.57 | - | - | - | 268.15 |
五、自由现金流量 | 96.63 | 739.38 | 738.22 | 859.96 | 906.43 | 924.93 | 680.21 |
自由现金流量增长率 | -0.16% | 16.49% | 5.40% | 2.04% | -26.46% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(23)张家界爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 613.98 | 2,769.59 | 3,046.57 | 3,541.77 | 3,895.97 | 4,207.64 | 4,207.64 |
减:营业成本 | 396.21 | 1,857.39 | 1,987.49 | 2,308.02 | 2,494.22 | 2,679.44 | 2,680.41 |
税金及附加 | 0.08 | 0.39 | 0.42 | 0.49 | 0.53 | 0.56 | 0.56 |
销售费用 | 61.62 | 259.43 | 283.54 | 301.32 | 325.20 | 348.40 | 349.76 |
管理费用 | 54.81 | 226.99 | 244.15 | 266.27 | 287.14 | 328.19 | 327.01 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
二、营业利润 | 101.26 | 425.39 | 530.97 | 665.67 | 788.88 | 851.05 | 849.90 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 101.26 | 425.39 | 530.97 | 665.67 | 788.88 | 851.05 | 849.90 |
减:所得税费用 | 25.32 | 106.35 | 132.74 | 166.42 | 197.22 | 212.76 | 212.48 |
四、净利润 | 75.94 | 319.04 | 398.23 | 499.25 | 591.66 | 638.29 | 637.42 |
净利润增长率 | 7.09% | 24.82% | 25.37% | 18.51% | 7.88% |
加:扣税后利息 | |||||||
加:折旧与摊销 | 44.05 | 187.70 | 189.34 | 261.36 | 261.31 | 261.36 | 258.92 |
减:营运资金增加 | 119.34 | 70.56 | 41.80 | 80.42 | 56.83 | 56.00 | - |
减:资本性支出(资本金追加) | - | 25.00 | 75.00 | 660.00 | 58.73 | - | 315.43 |
五、自由现金流量 | 0.65 | 411.18 | 470.77 | 20.19 | 737.41 | 843.65 | 580.91 |
自由现金流量增长率 | 14.49% | -95.71% | 3,552.35% | 14.41% | -31.14% | ||
折现率 | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% | 11.45% |
(24)百色爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 566.87 | 2,972.59 | 3,498.02 | 3,996.88 | 4,387.67 | 4,614.86 | 4,614.86 |
减:营业成本 | 337.20 | 1,654.24 | 1,867.93 | 2,134.30 | 2,341.95 | 2,463.39 | 2,463.19 |
税金及附加 | 0.10 | 0.51 | 0.55 | 0.59 | 0.63 | 0.65 | 0.66 |
销售费用 | 80.43 | 434.93 | 530.51 | 629.63 | 710.03 | 777.79 | 779.99 |
管理费用 | 111.53 | 578.32 | 702.90 | 831.05 | 946.75 | 1,037.68 | 1,037.54 |
财务费用 | - | - | - | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
资产处置收益 | |||||||
二、营业利润 | 37.61 | 304.59 | 396.13 | 401.31 | 388.31 | 335.35 | 333.48 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 37.61 | 304.59 | 396.13 | 401.31 | 388.31 | 335.35 | 333.48 |
减:所得税费用 | - | 33.16 | 99.03 | 100.33 | 97.08 | 83.84 | 83.37 |
四、净利润 | 37.61 | 271.43 | 297.10 | 300.98 | 291.23 | 251.51 | 250.11 |
净利润增长率 | 9.46% | 1.31% | -3.24% | -13.64% | 0.00% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 22.04 | 88.12 | 88.12 | 86.91 | 75.76 | 74.34 | 64.31 |
减:营运资金增加 | 41.30 | 73.06 | - | - | - | - | - |
减:资本性支出(资本金追加) | - | - | - | - | 68.10 | - | 86.14 |
五、自由现金流量 | 18.35 | 286.49 | 385.22 | 387.89 | 298.89 | 325.85 | 228.28 |
自由现金流量增长率 | 34.46% | 0.69% | -22.94% | 9.02% | -29.94% | ||
折现率 | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
(25)乐山爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年期 | |
一、营业收入 | 281.42 | 2,568.69 | 3,238.87 | 4,026.11 | 4,664.90 | 5,204.24 | 5,204.24 |
减:营业成本 | 300.66 | 1,877.48 | 2,223.16 | 2,624.48 | 2,957.69 | 3,233.90 | 3,239.53 |
营业税金及附加 | 0.10 | 0.82 | 1.01 | 1.24 | 1.42 | 1.58 | 1.58 |
销售费用 | 69.02 | 356.75 | 417.70 | 481.87 | 541.38 | 593.52 | 600.54 |
管理费用 | 65.41 | 299.76 | 339.19 | 385.04 | 424.72 | 459.78 | 462.62 |
研发费用 | - | ||||||
财务费用 | 1.52 | 6.96 | 2.39 | - | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
资产处置收益 | |||||||
二、营业利润 | -155.29 | 26.92 | 255.42 | 533.48 | 739.69 | 915.46 | 899.97 |
加:营业外收入 | |||||||
减:营业外支出 | |||||||
三、利润总额 | -155.29 | 26.92 | 255.42 | 533.48 | 739.69 | 915.46 | 899.97 |
减:所得税费用 | - | - | - | - | - | 220.04 | 224.99 |
四、净利润 | -155.29 | 26.92 | 255.42 | 533.48 | 739.69 | 695.42 | 674.98 |
净利润增长率 | -111.52% | 848.81% | 108.86% | 38.65% | -5.98% | ||
加:财务费用(扣除税务影响后) | |||||||
加:折旧与摊销 | 45.64 | 183.41 | 183.27 | 177.24 | 175.92 | 175.92 | 180.22 |
减:营运资金增加 | 13.13 | 177.42 | 125.18 | 148.36 | 119.77 | 84.00 | - |
减:资本性支出 | 10.00 | - | - | 65.38 | - | - | 235.17 |
减:偿还债务支出 | - | 140.00 | 110.00 | - | - | - | - |
加:借入债务 | 140.00 | 110.00 | - | - | - | - | - |
五、自由现金流量 | 7.22 | 2.91 | 203.51 | 496.98 | 795.84 | 787.34 | 620.03 |
自由现金流量增长率 | 6,893.47% | 144.20% | 60.14% | -1.07% | -21.25% | ||
折现率 | 11.60% | 11.57% | 11.47% | 11.47% | 11.47% | 11.47% | 11.47% |
(26)长治爱尔
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年期 | |
一、营业收入 | 411.19 | 2,354.69 | 2,701.72 | 3,059.44 | 3,392.72 | 3,653.33 | 3,653.33 |
减:营业成本 | 263.73 | 1,353.02 | 1,521.93 | 1,700.66 | 1,874.37 | 2,023.99 | 2,030.31 |
税金及附加 | 0.13 | 0.70 | 0.80 | 0.90 | 0.99 | 1.07 | 1.07 |
销售费用 | 73.37 | 324.32 | 366.06 | 410.09 | 450.96 | 481.11 | 483.86 |
管理费用 | 89.04 | 286.39 | 318.62 | 353.71 | 390.87 | 428.71 | 429.46 |
财务费用 | |||||||
信用减值损失 | |||||||
资产减值损失 | |||||||
二、营业利润 | -15.08 | 390.26 | 494.31 | 594.08 | 675.53 | 718.45 | 708.63 |
加:营业外收入 | |||||||
减:营业外支出 | |||||||
三、利润总额 | -15.08 | 390.26 | 494.31 | 594.08 | 675.53 | 718.45 | 708.63 |
减:所得税费用 | - | - | 123.58 | 148.52 | 168.88 | 179.61 | 177.16 |
四、净利润 | -15.08 | 390.26 | 370.73 | 445.56 | 506.65 | 538.84 | 531.47 |
净利润增长率 | 90.29% | -5.00% | 20.18% | 13.71% | 6.35% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 43.00 | 172.02 | 172.02 | 172.02 | 169.58 | 161.03 | 156.69 |
减:营运资金增加 | -10.60 | 37.63 | 28.71 | 39.13 | 35.58 | 26.95 | - |
减:资本性支出(资本金追加) | - | - | - | - | 58.58 | - | 183.07 |
五、自由现金流量 | 38.52 | 524.65 | 514.04 | 578.45 | 582.07 | 672.92 | 505.09 |
自由现金流量增长率 | -2.02% | 12.53% | 0.63% | 15.61% | -24.94% | ||
折现率 | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% | 11.44% |
(27)奥理德视光
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,064.94 | 5,088.10 | 5,805.30 | 6,551.20 | 7,197.40 | 7,753.20 | 7,753.20 |
减:营业成本 | 552.52 | 2,626.59 | 3,019.41 | 3,403.08 | 3,724.53 | 4,023.49 | 4,020.47 |
税金及附加 | 1.53 | 9.23 | 11.17 | 12.90 | 14.51 | 15.49 | 15.52 |
销售费用 | 19.25 | 185.74 | 209.80 | 235.29 | 255.35 | 272.72 | 273.55 |
管理费用 | 57.35 | 279.23 | 311.39 | 337.99 | 363.31 | 389.71 | 389.47 |
财务费用 | - | - | - | - | - | - | - |
资产减值损失 | - | - | - | - | - | - | - |
信用减值损失 | - | - | - | - | - | - | - |
加:公允价值变动收益 | |||||||
其他收益 | |||||||
二、营业利润 | 434.29 | 1,987.31 | 2,253.53 | 2,561.94 | 2,839.70 | 3,051.79 | 3,054.19 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 434.29 | 1,987.31 | 2,253.53 | 2,561.94 | 2,839.70 | 3,051.79 | 3,054.19 |
减:所得税费用 | 108.58 | 496.83 | 563.38 | 640.48 | 709.92 | 762.95 | 763.55 |
四、净利润 | 325.71 | 1,490.48 | 1,690.15 | 1,921.46 | 2,129.78 | 2,288.84 | 2,290.64 |
净利润增长率 | 9.26% | 13.40% | 13.69% | 10.84% | 7.47% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 63.90 | 261.61 | 260.28 | 258.24 | 236.15 | 226.05 | 220.04 |
减:营运资金增加 | 381.14 | 61.67 | 36.72 | 38.82 | 35.74 | 33.54 | - |
减:资本性支出(资本金追加) | 5.24 | 52.00 | 127.53 | - | 1,328.00 | 5.24 | 189.72 |
五、自由现金流量 | 3.23 | 1,638.42 | 1,786.18 | 2,140.88 | 1,002.19 | 2,476.11 | 2,320.96 |
自由现金流量增长率 | 9.02% | 19.86% | -53.19% | 147.07% | -6.27% | ||
折现率 | 11.39% | 11.39% | 11.39% | 11.39% | 11.39% | 11.39% | 11.39% |
(28)宣城眼科医院
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,003.19 | 4,529.83 | 5,108.53 | 5,721.48 | 6,408.18 | 7,152.11 | 7,152.11 |
减:营业成本 | 575.68 | 2,555.22 | 2,861.97 | 3,196.03 | 3,595.73 | 4,026.90 | 4,048.14 |
税金及附加 | 0.30 | 1.36 | 1.53 | 1.72 | 1.92 | 2.15 | 2.15 |
销售费用 | 78.65 | 210.40 | 226.79 | 251.98 | 282.73 | 313.29 | 320.66 |
管理费用 | 119.10 | 479.54 | 528.61 | 584.58 | 653.50 | 716.19 | 720.51 |
财务费用 | |||||||
资产减值损失 | |||||||
信用减值损失 | |||||||
加:投资收益 | |||||||
二、营业利润 | 229.46 | 1,283.31 | 1,489.63 | 1,687.17 | 1,874.30 | 2,093.58 | 2,060.65 |
加:营业外收入 | |||||||
减:营业外支出 | |||||||
三、利润总额 | 229.46 | 1,283.31 | 1,489.63 | 1,687.17 | 1,874.30 | 2,093.58 | 2,060.65 |
减:所得税费用 | 57.37 | 320.83 | 372.41 | 421.79 | 468.58 | 523.40 | 515.16 |
四、净利润 | 172.09 | 962.48 | 1,117.22 | 1,265.38 | 1,405.72 | 1,570.18 | 1,545.49 |
净利润增长率 | 13.64% | 16.08% | 13.26% | 11.09% | 11.70% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 33.87 | 131.97 | 124.57 | 128.60 | 132.61 | 145.87 | 150.49 |
减:营运资金增加 | 3.95 | 55.54 | 87.44 | 94.01 | 112.06 | 116.06 | - |
减:资本性支出(资本金追加) | - | - | - | 104.63 | - | 1,123.12 | 126.57 |
五、自由现金流量 | 202.01 | 1,038.91 | 1,154.35 | 1,195.34 | 1,426.27 | 476.87 | 1,569.41 |
自由现金流量增长率 | 11.11% | 3.55% | 19.32% | -66.57% | 229.11% | ||
折现率 | 11.47% | 11.47% | 11.47% | 11.47% | 11.47% | 11.47% | 11.47% |
(29)万州爱瑞
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 1,352.13 | 8,150.85 | 9,199.16 | 10,357.36 | 11,365.76 | 12,471.76 | 12,471.76 |
减:营业成本 | 858.71 | 4,430.92 | 4,784.09 | 5,130.19 | 5,520.33 | 5,978.17 | 6,104.45 |
税金及附加 | 0.12 | 0.51 | 0.53 | 0.55 | 0.58 | 0.59 | 0.59 |
销售费用 | 196.43 | 800.28 | 825.19 | 879.21 | 932.47 | 983.76 | 999.97 |
管理费用 | 280.43 | 1,243.37 | 1,335.31 | 1,434.47 | 1,532.93 | 1,639.45 | 1,643.06 |
财务费用 | 33.21 | 88.02 | 21.20 | 1.00 | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
资产处置收益 | |||||||
二、营业利润 | -16.77 | 1,587.75 | 2,232.84 | 2,911.94 | 3,379.45 | 3,869.79 | 3,723.69 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | -16.77 | 1,587.75 | 2,232.84 | 2,911.94 | 3,379.45 | 3,869.79 | 3,723.69 |
减:所得税费用 | -2.52 | 238.16 | 558.21 | 727.99 | 844.86 | 967.45 | 930.92 |
四、净利润 | -14.25 | 1,349.59 | 1,674.63 | 2,183.95 | 2,534.59 | 2,902.34 | 2,792.77 |
净利润增长率 | 12.83% | 24.08% | 30.41% | 16.06% | 14.51% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 118.33 | 511.98 | 425.10 | 296.26 | 244.11 | 274.83 | 420.09 |
减:营运资金增加 | 370.74 | 76.43 | 30.94 | 67.42 | 52.40 | 44.54 | - |
减:资本性支出(资本金追加) | - | 695.89 | - | - | - | 965.86 | 446.76 |
减:偿还债务支出 | 1,001.25 | 1,607.41 | 695.43 | 37.61 | - | - | - |
加:借入债务 | 1,280.00 | 530.00 | |||||
五、自由现金流量 | 12.09 | 11.84 | 1,373.36 | 2,375.18 | 2,726.30 | 2,166.77 | 2,766.10 |
自由现金流量增长率 | 11,499.32% | 72.95% | 14.78% | -20.52% | 27.66% | ||
折现率 | 11.97% | 11.65% | 11.49% | 11.46% | 11.45% | 11.45% | 11.45% |
(30)万州爱瑞-五桥
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 307.90 | 1,267.87 | 1,332.40 | 1,417.43 | 1,516.67 | 1,657.19 | 1,657.19 |
减:营业成本 | 157.36 | 658.78 | 674.25 | 706.57 | 756.88 | 842.17 | 843.21 |
税金及附加 | 0.03 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.05 |
销售费用 | 48.44 | 190.09 | 196.36 | 203.36 | 215.18 | 228.52 | 230.39 |
管理费用 | 25.79 | 102.47 | 108.20 | 114.79 | 122.07 | 130.79 | 130.76 |
财务费用 | 1.13 | 3.40 | 0.19 | 0.03 | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | 75.15 | 313.03 | 353.30 | 392.58 | 422.44 | 455.61 | 452.78 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 75.15 | 313.03 | 353.30 | 392.58 | 422.44 | 455.61 | 452.78 |
减:所得税费用 | 11.27 | 46.95 | 88.33 | 98.15 | 105.61 | 113.90 | 113.20 |
四、净利润 | 63.88 | 266.08 | 264.97 | 294.43 | 316.83 | 341.71 | 339.58 |
净利润增长率 | -12.24% | -0.42% | 11.12% | 7.61% | 7.85% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 13.96 | 55.95 | 26.55 | 8.93 | 8.93 | 35.34 | 38.22 |
减:营运资金增加 | 140.58 | -0.08 | 4.62 | 8.29 | 8.58 | 9.30 | - |
减:资本性支出(资本金追加) | - | 30.70 | - | - | - | 201.33 | 31.89 |
减:偿还债务支出 | 0.46 | 81.92 | 2.07 | 1.10 | - | - | - |
加:借入债务 | 80.00 | - | - | - | - | - | - |
五、自由现金流量 | 16.80 | 209.49 | 284.83 | 293.97 | 317.18 | 166.42 | 345.91 |
自由现金流量增长率 | 35.96% | 3.21% | 7.90% | -47.53% | 107.85% | ||
折现率 | 11.62% | 11.49% | 11.49% | 11.48% | 11.48% | 11.48% | 11.48% |
(31)开州爱瑞
单位:万元
项目/年度 | 预测数据 | ||||||
2019.10-12 | 2020 | 2021 | 2022 | 2023 | 2024 | 永续年限 | |
一、营业收入 | 550.33 | 2,535.53 | 2,858.40 | 3,174.28 | 3,470.65 | 3,718.10 | 3,718.10 |
减:营业成本 | 246.52 | 1,285.72 | 1,445.72 | 1,578.94 | 1,738.63 | 1,860.32 | 1,780.41 |
税金及附加 | 0.02 | 0.12 | 0.14 | 0.15 | 0.16 | 0.17 | 0.22 |
销售费用 | 44.68 | 207.75 | 228.97 | 251.01 | 277.01 | 305.25 | 307.26 |
管理费用 | 72.21 | 329.51 | 359.32 | 391.27 | 425.24 | 461.01 | 460.16 |
财务费用 | 10.73 | 30.69 | 12.45 | 1.25 | - | - | - |
信用减值损失 | |||||||
资产减值损失 | |||||||
加:其他收益 | |||||||
二、营业利润 | 176.17 | 681.74 | 811.80 | 951.66 | 1,029.61 | 1,091.35 | 1,170.05 |
加:营业外收入 | - | - | - | - | - | - | - |
减:营业外支出 | - | - | - | - | - | - | - |
三、利润总额 | 176.17 | 681.74 | 811.80 | 951.66 | 1,029.61 | 1,091.35 | 1,170.05 |
减:所得税费用 | 26.43 | 102.26 | 202.95 | 237.92 | 257.40 | 272.84 | 292.51 |
四、净利润 | 149.74 | 579.48 | 608.85 | 713.74 | 772.21 | 818.51 | 877.54 |
净利润增长率 | -7.88% | 5.07% | 17.23% | 8.19% | 6.00% | ||
加:扣税后利息 | |||||||
加:折旧与摊销 | 28.47 | 218.59 | 242.47 | 239.90 | 270.32 | 270.32 | 145.41 |
减:营运资金增加 | 275.36 | -27.77 | -9.92 | 2.98 | -1.56 | 4.96 | - |
减:资本性支出(资本金追加) | - | 541.30 | 150.00 | 510.32 | 150.00 | - | 152.30 |
减:偿还债务支出 | 193.12 | 647.87 | 430.54 | 25.39 | - | - | - |
加:借入债务 | 300.00 | 380.00 | - | - | - | - | - |
五、自由现金流量 | 9.73 | 16.67 | 280.70 | 414.95 | 894.09 | 1,083.87 | 870.65 |
自由现金流量增长率 | 1,583.86% | 47.83% | 115.47% | 21.23% | -19.67% | ||
折现率 | 11.93% | 11.87% | 11.50% | 11.47% | 11.46% | 11.46% | 11.46% |
2、量化分析标的公司未来收入增长率测算方法、收入增长来源及可实现性、确定依据及合理性各标的医院近二年一期及收益法预测期的收入增长率情况具体如下:
(1)阿迪娅爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 4,103.58 | 5,557.76 | 35.44% | 5,581.32 | 1,637.99 | 7,219.31 | 29.90% | 8,710.49 | 20.66% | 10,430.85 | 19.75% | 11,774.02 | 12.88% | 12,656.60 | 7.50% | 13,110.92 | 3.59% |
其中:屈光手术 | 6.59 | 111.45 | 1591.20% | 269.50 | 78.00 | 347.50 | 211.80% | 1,014.00 | 191.80% | 1,825.20 | 80.00% | 2,542.80 | 39.32% | 3,057.60 | 20.25% | 3,354.00 | 9.69% |
手术量次数(次) | 6.00 | 52.00 | 766.67% | 173.00 | 50.00 | 223.00 | 328.85% | 650.00 | 191.48% | 1,170.00 | 80.00% | 1,630.00 | 39.32% | 1,960.00 | 20.25% | 2,150.00 | 9.69% |
平均单价(万元) | 1.10 | 2.14 | 94.55% | 1.56 | 1.56 | 1.56 | -27.18% | 1.56 | 0.11% | 1.56 | 0.00% | 1.56 | 0.00% | 1.56 | 0.00% | 1.56 | 0.00% |
白内障 | 1,287.48 | 1,961.03 | 52.32% | 1,807.97 | 530.10 | 2,338.07 | 19.23% | 2,543.55 | 8.79% | 2,771.40 | 8.96% | 2,938.80 | 6.04% | 3,022.50 | 2.85% | 3,050.40 | 0.92% |
手术量次数(次) | 1,233.00 | 2,299.00 | 86.46% | 1,940.00 | 570.00 | 2,510.00 | 9.18% | 2,735.00 | 8.96% | 2,980.00 | 8.96% | 3,160.00 | 6.04% | 3,250.00 | 2.85% | 3,280.00 | 0.92% |
平均单价(万元) | 1.04 | 0.85 | -18.27% | 0.93 | 0.93 | 0.93 | 9.59% | 0.93 | -0.16% | 0.93 | 0.00% | 0.93 | 0.00% | 0.93 | 0.00% | 0.93 | 0.00% |
其他病种收入 | 2,809.51 | 3,485.28 | 24.05% | 3,503.85 | 1,029.89 | 4,533.74 | 30.08% | 5,152.94 | 13.66% | 5,834.25 | 13.22% | 6,292.42 | 7.85% | 6,576.50 | 4.51% | 6,706.52 | 1.98% |
净利润 | 85.74 | 127.54 | 48.75% | 430.86 | 14.51 | 445.37 | 249.20% | 783.98 | 76.03% | 863.14 | 10.10% | 1,005.88 | 16.54% | 1,107.95 | 10.15% | 1,158.12 | 4.53% |
(2)银川爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 3,184.69 | 4,676.50 | 46.84% | 4,404.47 | 1,468.00 | 5,872.47 | 25.57% | 6,479.42 | 10.34% | 7,038.90 | 8.63% | 7,534.92 | 7.05% | 7,987.01 | 6.00% | 8,420.24 | 5.42% |
其中:屈光手术 | 796.50 | 1,292.41 | 62.26% | 1,512.26 | 504.64 | 2,016.90 | 56.06% | 2,278.07 | 12.95% | 2,506.14 | 10.01% | 2,707.07 | 8.02% | 2,868.96 | 5.98% | 3,040.86 | 5.99% |
手术量次数(次) | 620.50 | 912.50 | 47.06% | 994.50 | 332.00 | 1,326.50 | 45.37% | 1,451.00 | 9.39% | 1,547.00 | 6.62% | 1,621.00 | 4.78% | 1,668.00 | 2.90% | 1,718.00 | 3.00% |
平均单价(万元) | 1.28 | 1.42 | 10.94% | 1.52 | 1.52 | 1.52 | 7.08% | 1.57 | 3.26% | 1.62 | 3.18% | 1.67 | 3.09% | 1.72 | 2.99% | 1.77 | 2.91% |
白内障 | 1,483.38 | 1,942.80 | 30.97% | 1,283.12 | 427.72 | 1,710.84 | -11.94% | 1,813.36 | 5.99% | 1,921.92 | 5.99% | 2,037.60 | 6.02% | 2,159.88 | 6.00% | 2,289.84 | 6.02% |
手术量次数(次) | 1,982.00 | 2,758.00 | 39.15% | 1,727.00 | 578.00 | 2,305.00 | -16.42% | 2,386.00 | 3.51% | 2,464.00 | 3.27% | 2,547.00 | 3.37% | 2,634.00 | 3.42% | 2,726.00 | 3.49% |
平均单价(万元) | 0.75 | 0.70 | -6.67% | 0.74 | 0.74 | 0.74 | 6.03% | 0.76 | 2.39% | 0.78 | 2.63% | 0.80 | 2.56% | 0.82 | 2.50% | 0.84 | 2.44% |
其他病种收入 | 904.81 | 1,441.29 | 59.29% | 1,609.09 | 535.64 | 2,144.73 | 48.81% | 2,387.99 | 11.34% | 2,610.84 | 9.33% | 2,790.25 | 6.87% | 2,958.17 | 6.02% | 3,089.54 | 4.44% |
净利润 | 156.30 | 379.73 | 142.95% | 702.61 | 245.71 | 948.32 | 149.74% | 1,141.71 | 20.39% | 1,076.91 | -5.68% | 1,175.47 | 9.15% | 1,183.99 | 0.72% | 1,225.48 | 3.50% |
(3)西宁爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 3,129.97 | 4,324.44 | 38.16% | 4,398.05 | 1,466.01 | 5,864.06 | 35.60% | 6,896.71 | 17.61% | 7,804.05 | 13.16% | 8,558.67 | 9.67% | 9,223.11 | 7.76% | 9,924.57 | 7.61% |
其中:屈光手术 | 449.40 | 665.83 | 48.16% | 861.07 | 287.56 | 1,148.63 | 72.51% | 1,377.35 | 19.91% | 1,584.24 | 15.02% | 1,790.55 | 13.02% | 1,968.68 | 9.95% | 2,166.72 | 10.06% |
手术量次数(次) | 366.50 | 523.50 | 42.84% | 545.50 | 182.00 | 727.50 | 38.97% | 845.00 | 16.15% | 943.00 | 11.60% | 1,035.00 | 9.76% | 1,106.00 | 6.86% | 1,184.00 | 7.05% |
平均单价(万元) | 1.23 | 1.27 | 3.25% | 1.58 | 1.58 | 1.58 | 24.32% | 1.63 | 3.24% | 1.68 | 3.07% | 1.73 | 2.98% | 1.78 | 2.89% | 1.83 | 2.81% |
白内障 | 1,711.68 | 2,334.28 | 36.37% | 2,101.33 | 700.70 | 2,802.03 | 20.04% | 3,222.00 | 14.99% | 3,543.86 | 9.99% | 3,756.68 | 6.01% | 3,981.90 | 6.00% | 4,221.60 | 6.02% |
手术量次数(次) | 2,627.00 | 3,886.00 | 47.93% | 3,017.00 | 1,001.00 | 4,018.00 | 3.40% | 4,475.00 | 11.37% | 4,789.00 | 7.02% | 4,943.00 | 3.22% | 5,105.00 | 3.28% | 5,277.00 | 3.37% |
平均单价(万元) | 0.65 | 0.60 | -7.69% | 0.70 | 0.70 | 0.70 | 16.23% | 0.72 | 3.25% | 0.74 | 2.78% | 0.76 | 2.70% | 0.78 | 2.63% | 0.80 | 2.56% |
其他病种收入 | 968.89 | 1,324.33 | 36.69% | 1,435.65 | 477.75 | 1,913.40 | 44.48% | 2,297.36 | 20.07% | 2,675.95 | 16.48% | 3,011.44 | 12.54% | 3,272.53 | 8.67% | 3,536.25 | 8.06% |
净利润 | -80.15 | 133.11 | NA | 168.39 | 75.45 | 243.84 | 83.19% | 200.51 | -17.77% | 840.53 | 319.20% | 848.37 | 0.93% | 1,029.12 | 21.31% | 1,280.53 | 24.43% |
(4)烟台爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 3,450.36 | 4,315.43 | 25.07% | 3,592.55 | 1,067.74 | 4,660.29 | 7.99% | 5,454.85 | 17.05% | 6,296.23 | 15.42% | 7,220.77 | 14.68% | 8,182.88 | 13.32% | 9,123.21 | 11.49% |
其中:屈光手术 | 730.14 | 1,175.68 | 61.02% | 1,241.10 | 143.65 | 1,384.75 | 17.78% | 1,831.08 | 32.23% | 2,318.54 | 26.62% | 2,850.21 | 22.93% | 3,411.68 | 19.70% | 4,005.76 | 17.41% |
手术量次数(次) | 578.00 | 830.00 | 43.60% | 864.00 | 100.00 | 964.00 | 16.14% | 1,214.00 | 25.93% | 1,464.00 | 20.59% | 1,714.00 | 17.08% | 1,954.00 | 14.00% | 2,185.00 | 11.82% |
平均单价(万元) | 1.26 | 1.42 | 12.14% | 1.44 | 1.44 | 1.44 | 1.41% | 1.51 | 5.00% | 1.58 | 5.00% | 1.66 | 5.00% | 1.75 | 5.00% | 1.83 | 5.00% |
白内障 | 1,778.24 | 2,066.58 | 16.21% | 1,365.58 | 648.87 | 2,014.45 | -2.52% | 2,147.18 | 6.59% | 2,276.50 | 6.02% | 2,402.10 | 5.52% | 2,515.44 | 4.72% | 2,615.62 | 3.98% |
手术量次数(次) | 3,393.00 | 3,520.00 | 3.74% | 1,810.00 | 860.00 | 2,670.00 | -24.15% | 2,790.00 | 4.49% | 2,900.00 | 3.94% | 3,000.00 | 3.45% | 3,080.00 | 2.67% | 3,140.00 | 1.95% |
平均单价(万元) | 0.52 | 0.59 | 12.02% | 0.75 | 0.75 | 0.75 | 28.51% | 0.77 | 2.00% | 0.79 | 2.00% | 0.80 | 2.00% | 0.82 | 2.00% | 0.83 | 2.00% |
其他病种收入 | 941.98 | 1,073.17 | 13.93% | 985.87 | 275.22 | 1,261.09 | 17.51% | 1,476.59 | 17.09% | 1,701.19 | 15.21% | 1,968.46 | 15.71% | 2,255.76 | 14.60% | 2,501.83 | 10.91% |
净利润 | 23.76 | 149.25 | 528.16% | 217.66 | -274.12 | -56.46 | -137.83% | 460.15 | NA | 817.59 | 77.68% | 679.05 | -16.94% | 1,102.15 | 62.31% | 1,534.64 | 39.24% |
(5)玉林爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,394.61 | 3,423.27 | 145.46% | 3,402.19 | 1,130.50 | 4,532.69 | 32.41% | 4,953.41 | 9.28% | 5,435.95 | 9.74% | 5,915.35 | 8.82% | 6,439.33 | 8.86% | 6,908.75 | 7.29% |
其中:屈光手术 | 404.64 | 851.83 | 110.52% | 1,226.05 | 408.36 | 1,634.41 | 91.87% | 1,877.80 | 14.89% | 2,166.30 | 15.36% | 2,448.50 | 13.03% | 2,775.36 | 13.35% | 3,052.56 | 9.99% |
手术量次数(次) | 381.00 | 692.50 | 81.76% | 746.50 | 249.00 | 995.50 | 43.75% | 1,145.00 | 15.02% | 1,305.00 | 13.97% | 1,475.00 | 13.03% | 1,652.00 | 12.00% | 1,817.00 | 9.99% |
平均单价(万元) | 1.06 | 1.23 | 16.04% | 1.64 | 1.64 | 1.64 | 33.48% | 1.64 | -0.11% | 1.66 | 1.22% | 1.66 | 0.00% | 1.68 | 1.20% | 1.68 | 0.00% |
白内障 | 626.44 | 1,922.60 | 206.91% | 1,516.53 | 502.28 | 2,018.81 | 5.00% | 2,084.47 | 3.25% | 2,162.40 | 3.74% | 2,242.36 | 3.70% | 2,325.00 | 3.69% | 2,409.75 | 3.65% |
手术量次数(次) | 2,159.00 | 3,975.00 | 84.11% | 2,598.00 | 866.00 | 3,464.00 | -12.86% | 3,533.00 | 1.99% | 3,604.00 | 2.01% | 3,676.00 | 2.00% | 3,750.00 | 2.01% | 3,825.00 | 2.00% |
平均单价(万元) | 0.29 | 0.48 | 65.52% | 0.58 | 0.58 | 0.58 | 21.42% | 0.59 | 1.24% | 0.60 | 1.69% | 0.61 | 1.67% | 0.62 | 1.64% | 0.63 | 1.61% |
其他病种收入 | 363.53 | 648.84 | 78.48% | 659.61 | 219.86 | 879.47 | 35.54% | 991.14 | 12.70% | 1,107.25 | 11.71% | 1,224.49 | 10.59% | 1,338.97 | 9.35% | 1,446.44 | 8.03% |
净利润 | -225.67 | 739.43 | NA | 957.76 | 324.05 | 1,281.81 | 73.35% | 1,408.02 | 9.85% | 1,247.80 | -11.38% | 1,314.43 | 5.34% | 1,391.49 | 5.86% | 1,497.34 | 7.61% |
(6)大连爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 752.12 | 2,505.62 | 233.14% | 3,204.48 | 1,070.54 | 4,275.02 | 70.62% | 5,463.80 | 27.81% | 6,741.79 | 23.39% | 8,018.23 | 18.93% | 9,078.96 | 13.23% | 9,908.44 | 9.14% |
其中:屈光手术 | 243.34 | 788.11 | 223.87% | 927.65 | 308.94 | 1,236.59 | 56.91% | 1,592.75 | 28.80% | 1,968.28 | 23.58% | 2,332.25 | 18.49% | 2,643.37 | 13.34% | 2,886.34 | 9.19% |
手术量次数(次) | 188.00 | 499.00 | 165.43% | 558.50 | 186.00 | 744.50 | 49.20% | 931.00 | 25.05% | 1,117.00 | 19.98% | 1,285.00 | 15.04% | 1,414.00 | 10.04% | 1,499.00 | 6.01% |
平均单价(万元) | 1.29 | 1.58 | 22.48% | 1.66 | 1.66 | 1.66 | 5.06% | 1.71 | 3.01% | 1.76 | 2.92% | 1.81 | 2.84% | 1.87 | 3.31% | 1.93 | 3.21% |
白内障 | 93.62 | 525.09 | 460.87% | 963.45 | 320.91 | 1,284.36 | 144.60% | 1,653.43 | 28.74% | 2,043.49 | 23.59% | 2,420.63 | 18.46% | 2,742.74 | 13.31% | 2,994.66 | 9.18% |
手术量次数(次) | 174.00 | 623.00 | 258.05% | 1,330.00 | 443.00 | 1,773.00 | 184.59% | 2,216.00 | 24.99% | 2,659.00 | 19.99% | 3,058.00 | 15.01% | 3,364.00 | 10.01% | 3,566.00 | 6.00% |
平均单价(万元) | 0.54 | 0.84 | 55.56% | 0.72 | 0.72 | 0.72 | -14.29% | 0.75 | 4.17% | 0.77 | 2.67% | 0.79 | 2.60% | 0.82 | 3.80% | 0.84 | 2.44% |
其他病种收入 | 385.39 | 1,158.59 | 200.63% | 1,272.18 | 426.96 | 1,699.14 | 46.66% | 2,161.03 | 27.18% | 2,671.74 | 23.63% | 3,205.32 | 19.97% | 3,631.02 | 13.28% | 3,963.75 | 9.16% |
净利润 | -1,259.56 | -879.25 | NA | -204.62 | -93.24 | -297.86 | NA | 63.19 | NA | 590.82 | 834.99% | 1,088.86 | 84.30% | 1,446.82 | 32.87% | 1,233.72 | -14.73% |
(7)十堰爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,687.13 | 2,756.65 | 63.39% | 3,136.07 | 533.74 | 3,669.81 | 33.13% | 4,272.88 | 16.43% | 4,868.84 | 13.95% | 5,515.72 | 13.29% | 6,149.20 | 11.49% | 6,741.08 | 9.63% |
其中:屈光手术 | 897.22 | 1,260.27 | 40.46% | 1,660.89 | 148.14 | 1,809.03 | 43.54% | 2,122.88 | 17.35% | 2,425.79 | 14.27% | 2,762.42 | 13.88% | 3,099.03 | 12.19% | 3,416.06 | 10.23% |
手术量次数(次) | 750.50 | 824.00 | 9.79% | 1,031.50 | 92.00 | 1,123.50 | 36.35% | 1,280.00 | 13.93% | 1,420.00 | 10.94% | 1,570.00 | 10.56% | 1,710.00 | 8.92% | 1,830.00 | 7.02% |
平均单价(万元) | 1.20 | 1.53 | 27.94% | 1.61 | 1.61 | 1.61 | 5.27% | 1.66 | 3.00% | 1.71 | 3.00% | 1.76 | 3.00% | 1.81 | 3.00% | 1.87 | 3.00% |
白内障 | 333.78 | 641.91 | 92.32% | 528.27 | 121.60 | 649.87 | 1.24% | 739.70 | 13.82% | 835.78 | 12.99% | 929.44 | 11.21% | 1,020.42 | 9.79% | 1,108.62 | 8.64% |
手术量次数(次) | 717.00 | 1,331.00 | 85.63% | 947.00 | 218.00 | 1,165.00 | -12.47% | 1,300.00 | 11.59% | 1,440.00 | 10.77% | 1,570.00 | 9.03% | 1,690.00 | 7.64% | 1,800.00 | 6.51% |
平均单价(万元) | 0.47 | 0.48 | 3.61% | 0.56 | 0.56 | 0.56 | 15.66% | 0.57 | 2.00% | 0.58 | 2.00% | 0.59 | 2.00% | 0.60 | 1.99% | 0.62 | 2.00% |
其他病种收入 | 456.13 | 854.47 | 87.33% | 946.91 | 264.00 | 1,210.91 | 41.71% | 1,410.30 | 16.47% | 1,607.27 | 13.97% | 1,823.86 | 13.48% | 2,029.75 | 11.29% | 2,216.40 | 9.20% |
净利润 | -5.16 | 220.89 | NA | 644.64 | -166.92 | 477.72 | 116.27% | 669.41 | 40.13% | 871.82 | 30.24% | 914.11 | 4.85% | 1,146.55 | 25.43% | 1,381.86 | 20.52% |
(8)梧州爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 2,343.12 | 3,931.35 | 67.78% | 3,052.07 | 1,018.48 | 4,070.55 | 3.54% | 4,396.08 | 8.00% | 4,763.02 | 8.35% | 5,149.09 | 8.11% | 5,575.93 | 8.29% | 5,992.30 | 7.47% |
其中:屈光手术 | 215.51 | 429.62 | 99.35% | 417.52 | 139.00 | 556.52 | 29.54% | 708.58 | 27.32% | 868.55 | 22.58% | 1,019.72 | 17.40% | 1,144.58 | 12.24% | 1,225.84 | 7.10% |
手术量次数(次) | 229.50 | 354.50 | 54.47% | 299.50 | 100.00 | 399.50 | 12.69% | 499.00 | 24.91% | 599.00 | 20.04% | 689.00 | 15.03% | 758.00 | 10.01% | 796.00 | 5.01% |
平均单价(万元) | 0.94 | 1.21 | 28.72% | 1.39 | 1.39 | 1.39 | 15.13% | 1.42 | 1.94% | 1.45 | 2.11% | 1.48 | 2.07% | 1.51 | 2.03% | 1.54 | 1.99% |
白内障 | 1,429.59 | 2,169.76 | 51.77% | 1,791.07 | 598.32 | 2,389.39 | 10.12% | 2,548.43 | 6.66% | 2,712.84 | 6.45% | 2,886.75 | 6.41% | 3,111.57 | 7.79% | 3,351.97 | 7.73% |
手术量次数(次) | 3,317.00 | 3,929.00 | 18.45% | 2,494.00 | 831.00 | 3,325.00 | -15.37% | 3,491.00 | 4.99% | 3,666.00 | 5.01% | 3,849.00 | 4.99% | 4,041.00 | 4.99% | 4,243.00 | 5.00% |
平均单价(万元) | 0.43 | 0.55 | 27.91% | 0.72 | 0.72 | 0.72 | 30.66% | 0.73 | 1.58% | 0.74 | 1.37% | 0.75 | 1.35% | 0.77 | 2.67% | 0.79 | 2.60% |
其他病种收入 | 698.02 | 1,331.97 | 90.82% | 843.48 | 281.16 | 1,124.64 | -15.57% | 1,139.07 | 1.28% | 1,181.63 | 3.74% | 1,242.62 | 5.16% | 1,319.78 | 6.21% | 1,414.49 | 7.18% |
净利润 | 62.85 | 467.69 | 644.14% | 618.96 | 153.70 | 772.66 | 65.21% | 872.91 | 12.97% | 792.24 | -9.24% | 893.94 | 12.84% | 1,150.66 | 28.72% | 1,238.31 | 7.62% |
(9)上饶爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,654.55 | 2,559.50 | 54.69% | 2,982.22 | 497.03 | 3,479.25 | 35.93% | 3,681.80 | 5.82% | 3,897.33 | 5.85% | 4,158.82 | 6.71% | 4,472.75 | 7.55% | 4,855.71 | 8.56% |
其中:屈光手术 | 497.26 | 816.18 | 64.14% | 1,158.02 | 193.00 | 1,351.02 | 65.53% | 1,418.57 | 5.00% | 1,489.50 | 5.00% | 1,578.87 | 6.00% | 1,689.39 | 7.00% | 1,824.54 | 8.00% |
手术量次数(次) | 534.00 | 600.50 | 12.45% | 752.50 | 125.00 | 877.50 | 46.13% | 904.00 | 3.02% | 931.00 | 2.99% | 969.00 | 4.08% | 1,018.00 | 5.06% | 1,080.00 | 6.09% |
平均单价(万元) | 0.93 | 1.36 | 46.24% | 1.54 | 1.54 | 1.54 | 13.21% | 1.57 | 1.97% | 1.60 | 1.91% | 1.63 | 1.87% | 1.66 | 1.84% | 1.69 | 1.81% |
白内障 | 439.85 | 613.43 | 39.46% | 575.93 | 95.99 | 671.92 | 9.53% | 705.52 | 5.00% | 740.80 | 5.00% | 785.25 | 6.00% | 840.22 | 7.00% | 915.84 | 9.00% |
手术量次数(次) | 972.00 | 1,257.00 | 29.32% | 1,018.00 | 168.00 | 1,186.00 | -5.65% | 1,216.00 | 2.53% | 1,256.00 | 3.29% | 1,309.00 | 4.22% | 1,377.00 | 5.19% | 1,477.00 | 7.26% |
平均单价(万元) | 0.45 | 0.49 | 8.89% | 0.57 | 0.57 | 0.57 | 15.62% | 0.58 | 2.38% | 0.59 | 1.72% | 0.60 | 1.69% | 0.61 | 1.67% | 0.62 | 1.64% |
其他病种收入 | 717.44 | 1,129.89 | 57.49% | 1,248.27 | 208.04 | 1,456.31 | 28.89% | 1,557.71 | 6.96% | 1,667.03 | 7.02% | 1,794.70 | 7.66% | 1,943.14 | 8.27% | 2,115.33 | 8.86% |
净利润 | -207.22 | -27.46 | NA | 464.89 | -91.51 | 373.38 | NA | 515.03 | 37.94% | 581.97 | 13.00% | 661.00 | 13.58% | 749.34 | 13.36% | 903.33 | 20.55% |
(10)大同爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,206.04 | 2,656.71 | 120.28% | 2,887.95 | 962.64 | 3,850.59 | 44.94% | 5,000.00 | 29.85% | 6,000.00 | 20.00% | 6,900.00 | 15.00% | 7,600.00 | 10.14% | 7,980.00 | 5.00% |
其中:屈光手术 | 342.10 | 656.85 | 92.01% | 828.73 | 276.12 | 1,104.85 | 68.20% | 1,435.06 | 29.89% | 1,793.75 | 24.99% | 2,153.01 | 20.03% | 2,475.13 | 14.96% | 2,723.56 | 10.04% |
手术量次数(次) | 329.50 | 607.00 | 84.22% | 710.00 | 236.00 | 946.00 | 55.85% | 1,186.00 | 25.37% | 1,435.00 | 20.99% | 1,669.00 | 16.31% | 1,861.00 | 11.50% | 1,988.00 | 6.82% |
平均单价(万元) | 1.04 | 1.08 | 3.85% | 1.17 | 1.17 | 1.17 | 8.14% | 1.21 | 3.60% | 1.25 | 3.31% | 1.29 | 3.20% | 1.33 | 3.10% | 1.37 | 3.01% |
白内障 | 414.76 | 902.82 | 117.67% | 692.10 | 230.58 | 922.68 | 2.20% | 1,061.45 | 15.04% | 1,167.14 | 9.96% | 1,225.44 | 5.00% | 1,287.23 | 5.04% | 1,351.23 | 4.97% |
手术量次数(次) | 982.00 | 1,727.00 | 75.87% | 1,105.00 | 366.00 | 1,471.00 | -14.82% | 1,633.00 | 11.01% | 1,742.00 | 6.67% | 1,776.00 | 1.95% | 1,813.00 | 2.08% | 1,851.00 | 2.10% |
平均单价(万元) | 0.42 | 0.52 | 23.81% | 0.63 | 0.63 | 0.63 | 20.62% | 0.65 | 3.63% | 0.67 | 3.08% | 0.69 | 2.99% | 0.71 | 2.90% | 0.73 | 2.82% |
其他病种收入 | 449.18 | 1,097.04 | 144.23% | 1,367.12 | 455.94 | 1,823.06 | 66.18% | 2,503.49 | 37.32% | 3,039.11 | 21.39% | 3,521.55 | 15.87% | 3,837.64 | 8.98% | 3,905.21 | 1.76% |
净利润 | -311.07 | 176.75 | NA | 651.12 | 214.03 | 865.15 | 389.48% | 1,146.01 | 32.46% | 1,217.75 | 6.26% | 1,364.29 | 12.03% | 1,452.45 | 6.46% | 1,415.16 | -2.57% |
(11)江门爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 540.42 | 1,823.01 | 237.33% | 2,842.95 | 947.42 | 3,790.37 | 107.92% | 5,391.75 | 42.25% | 6,679.07 | 23.88% | 7,500.70 | 12.30% | 7,943.24 | 5.90% | 8,171.01 | 2.87% |
其中:屈光手术 | 199.78 | 378.59 | 89.50% | 791.83 | 263.94 | 1,055.77 | 178.87% | 1,593.60 | 50.94% | 1,992.00 | 25.00% | 2,224.40 | 11.67% | 2,357.20 | 5.97% | 2,440.20 | 3.52% |
手术量次数(次) | 134.50 | 250.00 | 85.87% | 478.00 | 159.00 | 637.00 | 154.80% | 960.00 | 50.71% | 1,200.00 | 25.00% | 1,340.00 | 11.67% | 1,420.00 | 5.97% | 1,470.00 | 3.52% |
平均单价(万元) | 1.49 | 1.51 | 1.34% | 1.66 | 1.66 | 1.66 | 9.76% | 1.66 | 0.16% | 1.66 | 0.00% | 1.66 | 0.00% | 1.66 | 0.00% | 1.66 | 0.00% |
白内障 | 82.73 | 688.94 | 732.76% | 960.82 | 320.04 | 1,280.86 | 85.92% | 1,848.00 | 44.28% | 2,352.00 | 27.27% | 2,688.00 | 14.29% | 2,856.00 | 6.25% | 2,940.00 | 2.94% |
手术量次数(次) | 149.00 | 798.00 | 435.57% | 1,138.00 | 381.00 | 1,519.00 | 90.35% | 2,200.00 | 44.83% | 2,800.00 | 27.27% | 3,200.00 | 14.29% | 3,400.00 | 6.25% | 3,500.00 | 2.94% |
平均单价(万元) | 0.56 | 0.86 | 53.57% | 0.84 | 0.84 | 0.84 | -1.95% | 0.84 | -0.38% | 0.84 | 0.00% | 0.84 | 0.00% | 0.84 | 0.00% | 0.84 | 0.00% |
其他病种收入 | 257.91 | 755.48 | 192.92% | 1,090.30 | 363.44 | 1,453.74 | 92.43% | 1,950.15 | 34.15% | 2,335.07 | 19.74% | 2,588.30 | 10.84% | 2,730.04 | 5.48% | 2,790.81 | 2.23% |
净利润 | -443.72 | -176.06 | NA | 396.21 | 13.71 | 409.92 | NA | 510.53 | 24.54% | 585.01 | 14.59% | 671.66 | 14.81% | 724.31 | 7.84% | 759.65 | 4.88% |
(12)临汾爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,008.31 | 2,338.25 | 131.90% | 2,558.19 | 565.70 | 3,123.89 | 33.60% | 3,974.33 | 27.22% | 4,816.02 | 21.18% | 5,597.87 | 16.23% | 6,157.03 | 9.99% | 6,465.18 | 5.00% |
其中:屈光手术 | 417.93 | 732.98 | 75.38% | 912.38 | 89.70 | 1,002.08 | 36.71% | 1,407.74 | 40.48% | 1,689.70 | 20.03% | 1,942.92 | 14.99% | 2,137.20 | 10.00% | 2,244.50 | 5.02% |
手术量次数(次) | 477.00 | 726.00 | 52.20% | 794.50 | 78.00 | 872.50 | 20.18% | 1,193.00 | 36.73% | 1,385.00 | 16.09% | 1,542.00 | 11.34% | 1,644.00 | 6.61% | 1,675.00 | 1.89% |
平均单价(万元) | 0.88 | 1.01 | 14.77% | 1.15 | 1.15 | 1.15 | 13.71% | 1.18 | 2.74% | 1.22 | 3.39% | 1.26 | 3.28% | 1.30 | 3.17% | 1.34 | 3.08% |
白内障 | 250.83 | 749.92 | 198.98% | 630.43 | 196.00 | 826.43 | 10.20% | 972.66 | 17.69% | 1,167.00 | 19.98% | 1,342.30 | 15.02% | 1,476.48 | 10.00% | 1,550.34 | 5.00% |
手术量次数(次) | 756.00 | 1,625.00 | 114.95% | 1,118.00 | 350.00 | 1,468.00 | -9.66% | 1,677.00 | 14.24% | 1,945.00 | 15.98% | 2,165.00 | 11.31% | 2,307.00 | 6.56% | 2,349.00 | 1.82% |
平均单价(万元) | 0.33 | 0.46 | 39.39% | 0.56 | 0.56 | 0.56 | 22.38% | 0.58 | 3.03% | 0.60 | 3.45% | 0.62 | 3.33% | 0.64 | 3.23% | 0.66 | 3.13% |
其他病种收入 | 339.55 | 855.35 | 151.91% | 1,015.38 | 280.00 | 1,295.38 | 51.44% | 1,593.93 | 23.05% | 1,959.32 | 22.92% | 2,312.65 | 18.03% | 2,543.35 | 9.98% | 2,670.34 | 4.99% |
净利润 | -189.42 | -12.66 | NA | 213.17 | -111.91 | 101.26 | NA | 331.83 | 227.70% | 474.64 | 43.04% | 654.21 | 37.83% | 738.77 | 12.93% | 749.21 | 1.41% |
(13)东营爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,631.55 | 2,586.95 | 58.56% | 2,556.44 | 852.19 | 3,408.63 | 31.76% | 4,056.08 | 18.99% | 4,767.78 | 17.55% | 5,492.18 | 15.19% | 6,217.76 | 13.21% | 6,820.53 | 9.69% |
其中:屈光手术 | 374.70 | 653.60 | 74.43% | 758.90 | 253.20 | 1,012.10 | 54.85% | 1,199.93 | 18.56% | 1,400.22 | 16.69% | 1,604.15 | 14.56% | 1,819.08 | 13.40% | 1,951.75 | 7.29% |
手术量次数(次) | 410.00 | 576.00 | 40.49% | 563.50 | 188.00 | 751.50 | 30.47% | 865.00 | 15.10% | 980.00 | 13.29% | 1,090.00 | 11.22% | 1,200.00 | 10.09% | 1,250.00 | 4.17% |
平均单价(万元) | 0.91 | 1.13 | 24.16% | 1.35 | 1.35 | 1.35 | 18.69% | 1.39 | 3.00% | 1.43 | 3.00% | 1.47 | 3.00% | 1.52 | 3.00% | 1.56 | 3.00% |
白内障 | 561.59 | 748.08 | 33.21% | 619.20 | 206.22 | 825.42 | 10.34% | 948.43 | 14.90% | 1,063.65 | 12.15% | 1,178.42 | 10.79% | 1,296.70 | 10.04% | 1,382.93 | 6.65% |
手术量次数(次) | 1,503.00 | 1,498.00 | -0.33% | 1,132.00 | 377.00 | 1,509.00 | 0.73% | 1,700.00 | 12.66% | 1,869.00 | 9.94% | 2,030.00 | 8.61% | 2,190.00 | 7.88% | 2,290.00 | 4.57% |
平均单价(万元) | 0.37 | 0.50 | 33.67% | 0.55 | 0.55 | 0.55 | 9.53% | 0.56 | 1.99% | 0.57 | 2.01% | 0.58 | 2.00% | 0.59 | 2.00% | 0.60 | 1.99% |
其他病种收入 | 695.26 | 1,185.27 | 70.48% | 1,178.34 | 392.77 | 1,571.11 | 32.55% | 1,907.72 | 21.42% | 2,303.91 | 20.77% | 2,709.61 | 17.61% | 3,101.98 | 14.48% | 3,485.85 | 12.37% |
净利润 | -446.24 | -74.18 | NA | 142.22 | 34.77 | 176.99 | NA | 438.40 | 147.70% | 698.22 | 59.27% | 740.49 | 6.05% | 793.24 | 7.12% | 908.67 | 14.55% |
(14)德州爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 3,057.49 | 3,068.48 | 0.36% | 2,479.55 | 505.09 | 2,984.64 | -2.73% | 3,573.47 | 19.73% | 4,166.47 | 16.59% | 4,747.67 | 13.95% | 5,313.65 | 11.92% | 5,860.02 | 10.28% |
其中:屈光手术 | 997.09 | 1,374.82 | 37.88% | 1,411.77 | 234.57 | 1,646.34 | 19.75% | 2,037.23 | 23.74% | 2,388.62 | 17.25% | 2,764.90 | 15.75% | 3,138.14 | 13.50% | 3,491.40 | 11.26% |
手术量次数(次) | 1,106.50 | 1,299.00 | 17.40% | 1,131.50 | 188.00 | 1,319.50 | 1.58% | 1,570.00 | 18.98% | 1,770.00 | 12.74% | 1,970.00 | 11.30% | 2,150.00 | 9.14% | 2,300.00 | 6.98% |
平均单价(万元) | 0.90 | 1.06 | 17.46% | 1.25 | 1.25 | 1.25 | 17.89% | 1.30 | 4.00% | 1.35 | 4.00% | 1.40 | 4.00% | 1.46 | 4.00% | 1.52 | 4.00% |
白内障 | 1,058.05 | 750.75 | -29.04% | 385.00 | 64.07 | 449.07 | -40.18% | 507.28 | 12.96% | 575.93 | 13.53% | 623.24 | 8.21% | 663.66 | 6.49% | 698.06 | 5.18% |
手术量次数(次) | 3,787.00 | 2,055.00 | -45.74% | 685.00 | 114.00 | 799.00 | -61.12% | 885.00 | 10.76% | 985.00 | 11.30% | 1,045.00 | 6.09% | 1,091.00 | 4.40% | 1,125.00 | 3.12% |
平均单价(万元) | 0.28 | 0.37 | 30.74% | 0.56 | 0.56 | 0.56 | 53.86% | 0.57 | 1.99% | 0.58 | 2.01% | 0.60 | 2.00% | 0.61 | 2.00% | 0.62 | 2.01% |
其他病种收入 | 1,002.35 | 942.91 | -5.93% | 682.78 | 206.45 | 889.23 | -5.69% | 1,028.96 | 15.71% | 1,201.92 | 16.81% | 1,359.53 | 13.11% | 1,511.85 | 11.20% | 1,670.56 | 10.50% |
净利润 | 294.57 | 246.49 | -16.32% | 91.07 | -103.69 | -12.62 | -105.12% | 58.92 | NA | 223.06 | 278.58% | 448.96 | 101.27% | 654.91 | 45.87% | 1,045.63 | 59.66% |
(15)仙桃爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,585.26 | 2,183.45 | 37.73% | 2,479.26 | 612.81 | 3,092.08 | 41.61% | 3,410.37 | 10.29% | 3,711.20 | 8.82% | 4,001.75 | 7.83% | 4,247.69 | 6.15% | 4,465.65 | 5.13% |
其中:屈光手术 | 188.46 | 279.41 | 48.26% | 291.45 | 94.01 | 385.47 | 37.96% | 431.51 | 11.95% | 472.76 | 9.56% | 515.47 | 9.03% | 542.75 | 5.29% | 570.90 | 5.19% |
手术量次数(次) | 157.50 | 193.50 | 22.86% | 186.00 | 60.00 | 246.00 | 27.13% | 270.00 | 9.76% | 290.00 | 7.41% | 310.00 | 6.90% | 320.00 | 3.23% | 330.00 | 3.13% |
平均单价(万元) | 1.20 | 1.44 | 20.68% | 1.57 | 1.57 | 1.57 | 8.51% | 1.60 | 1.99% | 1.63 | 2.00% | 1.66 | 2.00% | 1.70 | 2.00% | 1.73 | 2.00% |
白内障 | 508.91 | 549.95 | 8.06% | 559.09 | 150.50 | 709.59 | 29.03% | 769.50 | 8.44% | 826.20 | 7.37% | 875.25 | 5.94% | 911.18 | 4.10% | 946.94 | 3.93% |
手术量次数(次) | 1,493.00 | 1,680.00 | 12.53% | 1,408.00 | 379.00 | 1,787.00 | 6.37% | 1,900.00 | 6.32% | 2,000.00 | 5.26% | 2,077.00 | 3.85% | 2,120.00 | 2.07% | 2,160.00 | 1.89% |
平均单价(万元) | 0.34 | 0.33 | -3.96% | 0.40 | 0.40 | 0.40 | 21.28% | 0.41 | 1.99% | 0.41 | 2.00% | 0.42 | 2.01% | 0.43 | 1.99% | 0.44 | 2.00% |
其他病种收入 | 887.89 | 1,354.09 | 52.51% | 1,628.72 | 368.30 | 1,997.02 | 47.48% | 2,209.36 | 10.63% | 2,412.24 | 9.18% | 2,611.03 | 8.24% | 2,793.76 | 7.00% | 2,947.81 | 5.51% |
净利润 | 106.76 | 171.38 | 60.53% | 448.85 | 91.83 | 540.68 | 215.49% | 689.22 | 27.47% | 773.79 | 12.27% | 854.79 | 10.47% | 911.41 | 6.62% | 969.31 | 6.35% |
(16)中山爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 624.59 | 1,555.68 | 149.07% | 2,465.93 | 822.53 | 3,288.46 | 111.38% | 3,974.46 | 20.86% | 4,739.12 | 19.24% | 5,541.67 | 16.93% | 6,276.73 | 13.26% | 6,881.81 | 9.64% |
其中:屈光手术 | 380.54 | 908.44 | 138.72% | 1,086.47 | 362.84 | 1,449.31 | 59.54% | 1,799.85 | 24.19% | 2,160.60 | 20.04% | 2,553.12 | 18.17% | 2,909.69 | 13.97% | 3,209.13 | 10.29% |
手术量次数(次) | 243.00 | 576.00 | 137.04% | 562.50 | 188.00 | 750.50 | 30.30% | 923.00 | 22.98% | 1,108.00 | 20.04% | 1,296.00 | 16.97% | 1,477.00 | 13.97% | 1,629.00 | 10.29% |
平均单价(万元) | 1.57 | 1.58 | 0.64% | 1.93 | 1.93 | 1.93 | 22.22% | 1.95 | 0.98% | 1.95 | 0.00% | 1.97 | 1.03% | 1.97 | 0.00% | 1.97 | 0.00% |
白内障 | 6.97 | 31.32 | 349.35% | 445.59 | 148.40 | 593.99 | 1796.52% | 637.00 | 7.24% | 726.18 | 14.00% | 813.40 | 12.01% | 894.74 | 10.00% | 966.28 | 8.00% |
手术量次数(次) | 9.00 | 32.00 | 255.56% | 420.00 | 140.00 | 560.00 | 1650.00% | 650.00 | 16.07% | 741.00 | 14.00% | 830.00 | 12.01% | 913.00 | 10.00% | 986.00 | 8.00% |
平均单价(万元) | 0.77 | 0.98 | 27.27% | 1.06 | 0.98 | 1.06 | 8.23% | 0.98 | -7.61% | 0.98 | 0.00% | 0.98 | 0.00% | 0.98 | 0.00% | 0.98 | 0.00% |
其他病种收入 | 237.08 | 615.92 | 159.79% | 933.87 | 311.29 | 1,245.16 | 102.16% | 1,537.61 | 23.49% | 1,852.34 | 20.47% | 2,175.15 | 17.43% | 2,472.30 | 13.66% | 2,706.40 | 9.47% |
净利润 | -407.43 | -274.61 | NA | 232.64 | 90.99 | 323.63 | NA | 535.30 | 65.40% | 605.09 | 13.04% | 775.43 | 28.15% | 975.41 | 25.79% | 1,117.33 | 14.55% |
(17)钦州爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,224.98 | 2,053.01 | 67.60% | 2,198.59 | 732.89 | 2,931.48 | 42.79% | 3,469.65 | 18.36% | 4,049.89 | 16.72% | 4,643.43 | 14.66% | 5,196.36 | 11.91% | 5,571.95 | 7.23% |
其中:屈光手术 | 243.80 | 465.15 | 90.79% | 672.45 | 223.52 | 895.97 | 92.62% | 1,108.48 | 23.72% | 1,340.31 | 20.91% | 1,566.50 | 16.88% | 1,768.50 | 12.89% | 1,907.40 | 7.85% |
手术量次数(次) | 240.00 | 385.50 | 60.63% | 528.00 | 176.00 | 704.00 | 82.62% | 866.00 | 23.01% | 1,039.00 | 19.98% | 1,205.00 | 15.98% | 1,350.00 | 12.03% | 1,445.00 | 7.04% |
平均单价(万元) | 1.02 | 1.21 | 18.63% | 1.27 | 1.27 | 1.27 | 5.18% | 1.28 | 0.57% | 1.29 | 0.78% | 1.30 | 0.78% | 1.31 | 0.77% | 1.32 | 0.76% |
白内障 | 639.28 | 1,093.31 | 71.02% | 957.98 | 320.00 | 1,277.98 | 16.89% | 1,482.15 | 15.98% | 1,700.58 | 14.74% | 1,932.42 | 13.63% | 2,155.12 | 11.52% | 2,283.60 | 5.96% |
手术量次数(次) | 1,770.00 | 2,515.00 | 42.09% | 2,399.00 | 800.00 | 3,199.00 | 27.20% | 3,615.00 | 13.00% | 4,049.00 | 12.01% | 4,494.00 | 10.99% | 4,898.00 | 8.99% | 5,190.00 | 5.96% |
平均单价(万元) | 0.36 | 0.43 | 19.44% | 0.40 | 0.40 | 0.40 | -7.09% | 0.41 | 2.63% | 0.42 | 2.44% | 0.43 | 2.38% | 0.44 | 2.33% | 0.44 | 0.00% |
其他病种收入 | 341.90 | 494.55 | 44.65% | 568.16 | 189.37 | 757.53 | 53.18% | 879.02 | 16.04% | 1,009.00 | 14.79% | 1,144.51 | 13.43% | 1,272.74 | 11.20% | 1,380.95 | 8.50% |
净利润 | -82.73 | 205.27 | NA | 397.57 | 114.46 | 512.03 | 149.44% | 655.38 | 28.00% | 600.15 | -8.43% | 720.43 | 20.04% | 883.21 | 22.59% | 1,000.46 | 13.28% |
(18)延吉爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,484.76 | 2,114.06 | 42.38% | 2,085.95 | 564.34 | 2,650.29 | 25.36% | 3,401.41 | 28.34% | 4,027.50 | 18.41% | 4,672.81 | 16.02% | 5,157.52 | 10.37% | 5,471.07 | 6.08% |
其中:屈光手术 | 546.08 | 707.27 | 29.52% | 747.12 | 196.80 | 943.92 | 33.46% | 1,107.00 | 17.28% | 1,295.60 | 17.04% | 1,443.20 | 11.39% | 1,549.80 | 7.39% | 1,599.00 | 3.17% |
手术量次数(次) | 424.50 | 490.50 | 15.55% | 455.00 | 120.00 | 575.00 | 17.23% | 675.00 | 17.39% | 790.00 | 17.04% | 880.00 | 11.39% | 945.00 | 7.39% | 975.00 | 3.17% |
平均单价(万元) | 1.29 | 1.44 | 11.63% | 1.64 | 1.64 | 1.64 | 14.00% | 1.64 | -0.10% | 1.64 | 0.00% | 1.64 | 0.00% | 1.64 | 0.00% | 1.64 | 0.00% |
白内障 | 326.82 | 510.71 | 56.27% | 464.78 | 132.30 | 597.08 | 16.91% | 671.30 | 12.43% | 749.70 | 11.68% | 818.30 | 9.15% | 867.30 | 5.99% | 891.80 | 2.82% |
手术量次数(次) | 609.00 | 1,085.00 | 78.16% | 951.00 | 270.00 | 1,221.00 | 12.53% | 1,370.00 | 12.20% | 1,370.00 | 0.00% | 1,530.00 | 11.68% | 1,670.00 | 9.15% | 1,770.00 | 5.99% |
平均单价(万元) | 0.54 | 0.47 | -12.96% | 0.49 | 0.49 | 0.49 | 4.04% | 0.49 | 0.20% | 0.49 | 0.00% | 0.49 | 0.00% | 0.49 | 0.00% | 0.49 | 0.00% |
其他病种收入 | 611.86 | 896.08 | 46.45% | 874.05 | 235.24 | 1,109.29 | 23.79% | 1,623.11 | 46.32% | 1,982.20 | 22.12% | 2,411.31 | 21.65% | 2,740.42 | 13.65% | 2,980.27 | 8.75% |
净利润 | -107.19 | 152.07 | NA | 305.41 | 81.56 | 386.97 | 154.47% | 453.58 | 17.21% | 550.45 | 21.36% | 639.56 | 16.19% | 705.32 | 10.28% | 750.03 | 6.34% |
(19)柳州爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,196.91 | 2,318.99 | 93.75% | 1,964.51 | 713.84 | 2,678.35 | 15.50% | 3,239.98 | 20.97% | 3,742.71 | 15.52% | 4,271.52 | 14.13% | 4,720.12 | 10.50% | 5,109.73 | 8.25% |
其中:屈光手术 | 208.63 | 667.37 | 219.88% | 785.50 | 283.05 | 1,068.55 | 60.11% | 1,300.45 | 21.70% | 1,508.15 | 15.97% | 1,725.43 | 14.41% | 1,898.13 | 10.01% | 2,031.58 | 7.03% |
手术量次数(次) | 199.00 | 556.00 | 179.40% | 514.50 | 185.00 | 699.50 | 25.81% | 839.00 | 19.94% | 973.00 | 15.97% | 1,099.00 | 12.95% | 1,209.00 | 10.01% | 1,294.00 | 7.03% |
平均单价(万元) | 1.05 | 1.20 | 14.29% | 1.53 | 1.53 | 1.53 | 27.30% | 1.55 | 1.47% | 1.55 | 0.00% | 1.57 | 1.29% | 1.57 | 0.00% | 1.57 | 0.00% |
白内障 | 477.61 | 861.05 | 80.28% | 607.49 | 203.40 | 810.89 | -5.83% | 939.32 | 15.84% | 1,042.82 | 11.02% | 1,161.37 | 11.37% | 1,254.43 | 8.01% | 1,357.92 | 8.25% |
手术量次数(次) | 1,414.00 | 2,417.00 | 70.93% | 1,355.00 | 452.00 | 1,807.00 | -25.24% | 2,042.00 | 13.00% | 2,267.00 | 11.02% | 2,471.00 | 9.00% | 2,669.00 | 8.01% | 2,829.00 | 5.99% |
平均单价(万元) | 0.34 | 0.36 | 5.88% | 0.45 | 0.45 | 0.45 | 24.65% | 0.46 | 2.51% | 0.46 | 0.00% | 0.47 | 2.17% | 0.47 | 0.00% | 0.48 | 2.13% |
其他病种收入 | 510.67 | 790.57 | 54.81% | 571.52 | 227.39 | 798.91 | 1.05% | 1,000.21 | 25.20% | 1,191.74 | 19.15% | 1,384.72 | 16.19% | 1,567.56 | 13.20% | 1,720.23 | 9.74% |
净利润 | -385.76 | -69.46 | NA | 100.83 | 90.71 | 191.54 | NA | 421.41 | 120.01% | 441.04 | 4.66% | 549.74 | 24.65% | 622.88 | 13.30% | 674.63 | 8.31% |
(20)安庆爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 2,132.28 | 2,111.56 | -0.97% | 1,940.71 | 556.94 | 2,497.65 | 18.28% | 2,909.34 | 16.48% | 3,331.04 | 14.49% | 3,744.27 | 12.41% | 4,088.32 | 9.19% | 4,376.31 | 7.04% |
其中:屈光手术 | 323.13 | 422.24 | 30.67% | 572.64 | 152.56 | 725.20 | 71.75% | 845.03 | 16.52% | 967.31 | 14.47% | 1,086.83 | 12.36% | 1,186.04 | 9.13% | 1,270.44 | 7.12% |
手术量次数(次) | 375.00 | 438.50 | 16.93% | 518.00 | 138.00 | 656.00 | 49.60% | 735.00 | 12.04% | 809.00 | 10.07% | 874.00 | 8.03% | 926.00 | 5.95% | 963.00 | 4.00% |
平均单价(万元) | 0.86 | 0.96 | 11.63% | 1.11 | 1.11 | 1.11 | 15.63% | 1.15 | 3.60% | 1.20 | 4.35% | 1.24 | 3.33% | 1.28 | 3.23% | 1.32 | 3.13% |
白内障 | 973.78 | 892.06 | -8.39% | 638.11 | 149.19 | 787.30 | -11.74% | 916.87 | 16.46% | 1,049.25 | 14.44% | 1,178.40 | 12.31% | 1,286.34 | 9.16% | 1,378.11 | 7.13% |
手术量次数(次) | 1,843.00 | 1,442.00 | -21.76% | 988.00 | 231.00 | 1,219.00 | -15.46% | 1,365.00 | 11.98% | 1,502.00 | 10.04% | 1,622.00 | 7.99% | 1,719.00 | 5.98% | 1,788.00 | 4.01% |
平均单价(万元) | 0.53 | 0.62 | 16.98% | 0.65 | 0.65 | 0.65 | 4.84% | 0.67 | 3.08% | 0.70 | 4.48% | 0.73 | 4.29% | 0.75 | 2.74% | 0.77 | 2.67% |
其他病种收入 | 835.37 | 797.26 | -4.56% | 729.96 | 255.19 | 985.15 | 23.57% | 1,147.44 | 16.47% | 1,314.48 | 14.56% | 1,479.04 | 12.52% | 1,615.94 | 9.26% | 1,727.76 | 6.92% |
净利润 | 47.63 | -92.80 | -294.84% | 176.18 | -63.40 | 112.78 | NA | 249.38 | 121.12% | 373.93 | 49.94% | 541.48 | 44.81% | 634.84 | 17.24% | 720.68 | 13.52% |
(21)玉溪爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,953.02 | 2,897.91 | 48.38% | 1,938.45 | 385.56 | 2,324.01 | -19.80% | 2,821.45 | 21.40% | 3,364.49 | 19.25% | 3,897.47 | 15.84% | 4,417.53 | 13.34% | 4,856.86 | 9.95% |
其中:屈光手术 | 1.35 | 7.03 | 420.74% | 162.16 | 53.71 | 215.87 | 2970.70% | 297.48 | 37.81% | 380.86 | 28.03% | 448.00 | 17.63% | 503.36 | 12.36% | 565.02 | 12.25% |
手术量次数(次) | 1.00 | 2.00 | 100.00% | 123.50 | 41.00 | 164.50 | 8125.00% | 222.00 | 34.95% | 278.00 | 25.23% | 320.00 | 15.11% | 352.00 | 10.00% | 387.00 | 9.94% |
平均单价(万元) | 1.35 | 3.52 | 160.74% | 1.31 | 1.31 | 1.31 | -62.72% | 1.34 | 2.11% | 1.37 | 2.24% | 1.40 | 2.19% | 1.43 | 2.14% | 1.46 | 2.10% |
白内障 | 1,268.79 | 1,850.70 | 45.86% | 883.73 | 84.10 | 967.83 | -47.70% | 1,173.60 | 21.26% | 1,406.78 | 19.87% | 1,655.68 | 17.69% | 1,912.02 | 15.48% | 2,108.00 | 10.25% |
手术量次数(次) | 2,339.00 | 4,206.00 | 79.82% | 1,513.00 | 145.00 | 1,658.00 | -60.58% | 1,956.00 | 17.97% | 2,269.00 | 16.00% | 2,587.00 | 14.01% | 2,897.00 | 11.98% | 3,100.00 | 7.01% |
平均单价(万元) | 0.54 | 0.44 | -18.52% | 0.58 | 0.58 | 0.58 | 32.67% | 0.60 | 2.79% | 0.62 | 3.33% | 0.64 | 3.23% | 0.66 | 3.13% | 0.68 | 3.03% |
其他病种收入 | 682.88 | 1,040.18 | 52.32% | 892.56 | 247.75 | 1,140.31 | 9.63% | 1,350.37 | 18.42% | 1,576.85 | 16.77% | 1,793.79 | 13.76% | 2,002.15 | 11.62% | 2,183.84 | 9.07% |
净利润 | -94.00 | -13.36 | NA | -3.75 | -116.15 | -119.90 | NA | 13.33 | NA | 206.55 | 1449.51% | 358.64 | 73.63% | 435.44 | 21.41% | 568.30 | 30.51% |
(22)铜陵爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,210.78 | 1,700.04 | 40.41% | 1,889.04 | 629.68 | 2,518.72 | 48.16% | 2,770.61 | 10.00% | 3,003.87 | 8.42% | 3,242.77 | 7.95% | 3,463.74 | 6.81% | 3,647.28 | 5.30% |
其中:屈光手术 | 349.83 | 550.95 | 57.49% | 779.01 | 259.67 | 1,038.68 | 88.53% | 1,142.55 | 10.00% | 1,233.95 | 8.00% | 1,332.67 | 8.00% | 1,425.96 | 7.00% | 1,497.26 | 5.00% |
手术量次数(次) | 534.00 | 600.50 | 12.45% | 603.00 | 201.00 | 804.00 | 33.89% | 879.00 | 9.33% | 942.00 | 7.17% | 1,010.00 | 7.22% | 1,072.00 | 6.14% | 1,117.00 | 4.20% |
平均单价(万元) | 0.66 | 0.92 | 39.39% | 1.29 | 1.29 | 1.29 | 40.42% | 1.30 | 0.63% | 1.31 | 0.77% | 1.32 | 0.76% | 1.33 | 0.76% | 1.34 | 0.75% |
白内障 | 410.78 | 513.32 | 24.96% | 447.41 | 149.14 | 596.55 | 16.21% | 656.21 | 10.00% | 708.71 | 8.00% | 751.23 | 6.00% | 781.28 | 4.00% | 796.91 | 2.00% |
手术量次数(次) | 972.00 | 1,257.00 | 29.32% | 806.00 | 266.00 | 1,072.00 | -14.72% | 1,151.00 | 7.37% | 1,222.00 | 6.17% | 1,273.00 | 4.17% | 1,302.00 | 2.28% | 1,306.00 | 0.31% |
平均单价(万元) | 0.42 | 0.41 | -2.38% | 0.56 | 0.56 | 0.56 | 35.73% | 0.57 | 2.43% | 0.58 | 1.75% | 0.59 | 1.72% | 0.60 | 1.69% | 0.61 | 1.67% |
其他病种收入 | 450.17 | 635.77 | 41.23% | 662.62 | 220.87 | 883.49 | 38.96% | 971.85 | 10.00% | 1,061.21 | 9.19% | 1,158.87 | 9.20% | 1,256.50 | 8.42% | 1,353.11 | 7.69% |
净利润 | -87.64 | 110.13 | NA | 372.05 | 129.53 | 501.58 | 355.44% | 569.24 | 13.49% | 634.09 | 11.39% | 701.25 | 10.59% | 746.88 | 6.51% | 784.81 | 5.08% |
(23)张家界爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 568.62 | 1,553.32 | 173.17% | 1,841.92 | 613.98 | 2,455.90 | 58.11% | 2,769.59 | 12.77% | 3,046.57 | 10.00% | 3,541.77 | 16.25% | 3,895.97 | 10.00% | 4,207.64 | 8.00% |
其中:屈光手术 | 154.15 | 422.80 | 174.28% | 566.31 | 188.77 | 755.08 | 78.59% | 853.24 | 13.00% | 938.56 | 10.00% | 1,079.34 | 15.00% | 1,187.27 | 10.00% | 1,282.25 | 8.00% |
手术量次数(次) | 128.50 | 291.50 | 126.85% | 386.00 | 128.00 | 514.00 | 76.33% | 577.00 | 12.26% | 630.00 | 9.19% | 720.00 | 14.29% | 781.00 | 8.47% | 833.00 | 6.66% |
平均单价(万元) | 1.20 | 1.45 | 20.83% | 1.47 | 1.47 | 1.47 | 1.31% | 1.48 | 0.75% | 1.49 | 0.68% | 1.50 | 0.67% | 1.52 | 1.33% | 1.54 | 1.32% |
白内障 | 149.41 | 429.11 | 187.20% | 476.55 | 158.85 | 635.40 | 48.07% | 718.00 | 13.00% | 789.80 | 10.00% | 908.27 | 15.00% | 999.10 | 10.00% | 1,079.03 | 8.00% |
手术量次数(次) | 411.00 | 932.00 | 126.76% | 901.00 | 300.00 | 1,201.00 | 28.86% | 1,330.00 | 10.74% | 1,436.00 | 7.97% | 1,622.00 | 12.95% | 1,753.00 | 8.08% | 1,860.00 | 6.10% |
平均单价(万元) | 0.36 | 0.46 | 27.78% | 0.53 | 0.53 | 0.53 | 15.01% | 0.54 | 2.07% | 0.55 | 1.85% | 0.56 | 1.82% | 0.57 | 1.79% | 0.58 | 1.75% |
其他病种收入 | 265.06 | 701.41 | 164.62% | 799.06 | 266.36 | 1,065.42 | 51.90% | 1,198.35 | 12.48% | 1,318.21 | 10.00% | 1,554.16 | 17.90% | 1,709.60 | 10.00% | 1,846.36 | 8.00% |
净利润 | -221.76 | -5.42 | NA | 221.99 | 75.94 | 297.93 | NA% | 319.04 | 7.09% | 398.23 | 24.82% | 499.25 | 25.37% | 591.66 | 18.51% | 638.29 | 7.88% |
(24)百色爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 205.16 | 950.75 | 363.42% | 1,701.28 | 566.87 | 2,268.15 | 138.56% | 2,972.59 | 31.06% | 3,498.02 | 17.68% | 3,996.88 | 14.26% | 4,387.67 | 9.78% | 4,614.86 | 5.18% |
其中:屈光手术 | 91.57 | 323.29 | 253.05% | 522.30 | 173.60 | 695.90 | 115.26% | 852.50 | 22.50% | 976.50 | 14.55% | 1,085.00 | 11.11% | 1,162.50 | 7.14% | 1,209.00 | 4.00% |
手术量次数(次) | 73.00 | 242.00 | 231.51% | 336.00 | 112.00 | 448.00 | 85.12% | 550.00 | 22.77% | 630.00 | 14.55% | 700.00 | 11.11% | 750.00 | 7.14% | 780.00 | 4.00% |
平均单价(万元) | 1.25 | 1.34 | 7.20% | 1.55 | 1.55 | 1.55 | 15.92% | 1.55 | -0.22% | 1.55 | 0.00% | 1.55 | 0.00% | 1.55 | 0.00% | 1.55 | 0.00% |
白内障 | 16.46 | 260.69 | 1483.78% | 616.58 | 205.80 | 822.38 | 215.46% | 1,029.00 | 25.12% | 1,225.00 | 19.05% | 1,421.00 | 16.00% | 1,568.00 | 10.34% | 1,641.50 | 4.69% |
手术量次数(次) | 48.00 | 747.00 | 1456.25% | 1,258.00 | 420.00 | 1,678.00 | 124.63% | 2,100.00 | 25.15% | 2,500.00 | 19.05% | 2,900.00 | 16.00% | 3,200.00 | 10.34% | 3,350.00 | 4.69% |
平均单价(万元) | 0.34 | 0.35 | 2.94% | 0.49 | 0.49 | 0.49 | 40.03% | 0.49 | -0.02% | 0.49 | 0.00% | 0.49 | 0.00% | 0.49 | 0.00% | 0.49 | 0.00% |
其他病种收入 | 97.13 | 366.77 | 277.61% | 562.40 | 187.47 | 749.87 | 104.45% | 1,091.09 | 45.50% | 1,296.52 | 18.83% | 1,490.88 | 14.99% | 1,657.17 | 11.15% | 1,764.36 | 6.47% |
净利润 | -262.13 | -253.18 | NA | 341.13 | 37.61 | 271.43 | NA | 297.10 | 9.46% | 300.98 | 1.31% | 291.23 | -3.24% | 251.51 | -13.64% | 251.51 | 0.00% |
(25)乐山爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 578.38 | 1,411.47 | 144.04% | 1,617.18 | 281.42 | 1,898.60 | 34.51% | 2,568.69 | 35.29% | 3,238.87 | 26.09% | 4,026.11 | 24.31% | 4,664.90 | 15.87% | 5,204.24 | 11.56% |
其中:屈光手术 | 93.74 | 245.56 | 161.96% | 210.16 | 56.46 | 266.62 | 8.58% | 441.53 | 65.60% | 730.84 | 65.52% | 1,204.42 | 64.80% | 1,538.22 | 27.71% | 1,821.19 | 18.40% |
手术量次数(次) | 74.00 | 155.00 | 109.46% | 134.00 | 36.00 | 170.00 | 9.68% | 272.00 | 60.00% | 435.00 | 59.93% | 696.00 | 60.00% | 863.00 | 23.99% | 992.00 | 14.95% |
平均单价(万元) | 1.28 | 1.59 | 24.22% | 1.57 | 1.57 | 1.57 | -1.26% | 1.62 | 3.18% | 1.68 | 3.70% | 1.73 | 2.98% | 1.78 | 2.89% | 1.84 | 3.37% |
白内障 | 300.52 | 943.30 | 213.89% | 1,210.15 | 161.42 | 1,371.57 | 45.40% | 1,703.49 | 24.20% | 1,939.21 | 13.84% | 2,097.37 | 8.16% | 2,268.33 | 8.15% | 2,453.46 | 8.16% |
手术量次数(次) | 815.00 | 1,903.00 | 133.50% | 2,444.00 | 326.00 | 2,770.00 | 45.56% | 3,324.00 | 20.00% | 3,656.00 | 9.99% | 3,839.00 | 5.01% | 4,031.00 | 5.00% | 4,233.00 | 5.01% |
平均单价(万元) | 0.37 | 0.50 | 35.14% | 0.50 | 0.50 | 0.50 | 0.00% | 0.51 | 2.00% | 0.53 | 3.92% | 0.55 | 3.77% | 0.56 | 1.82% | 0.58 | 3.57% |
其他病种收入 | 184.12 | 222.61 | 20.90% | 196.87 | 63.54 | 260.41 | 16.98% | 423.67 | 62.69% | 568.82 | 34.26% | 724.32 | 27.34% | 858.35 | 18.50% | 929.59 | 8.30% |
净利润 | -500.95 | -390.89 | NA | -78.47 | -155.29 | -233.76 | NA | 26.92 | NA | 255.42 | 848.81% | 533.48 | 108.86% | 739.69 | 38.65% | 695.42 | -5.98% |
(26)长治爱尔
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | - | 731.35 | / | 1,586.15 | 411.19 | 1,997.34 | 173.10% | 2,354.69 | 17.89% | 2,701.72 | 14.74% | 3,059.44 | 13.24% | 3,392.72 | 10.89% | 3,653.33 | 7.68% |
其中:屈光手术 | - | 321.06 | / | 676.96 | 135.68 | 812.64 | 153.11% | 954.69 | 17.48% | 1,090.82 | 14.26% | 1,239.66 | 13.64% | 1,373.73 | 10.82% | 1,485.60 | 8.14% |
手术量次数(次) | - | 268.00 | / | 474.00 | 95.00 | 569.00 | 112.31% | 649.00 | 14.06% | 727.00 | 12.02% | 810.00 | 11.42% | 880.00 | 8.64% | 933.00 | 6.02% |
平均单价(万元) | - | 1.20 | / | 1.43 | 1.43 | 1.43 | 19.17% | 1.47 | 2.80% | 1.50 | 2.04% | 1.53 | 2.00% | 1.56 | 1.96% | 1.59 | 1.92% |
白内障 | - | 139.22 | / | 397.58 | 132.53 | 530.11 | 280.77% | 622.46 | 17.42% | 711.26 | 14.27% | 797.95 | 12.19% | 878.91 | 10.15% | 950.21 | 8.11% |
手术量次数(次) | - | 325.00 | / | 1,023.00 | 341.00 | 1,364.00 | 319.69% | 1,555.00 | 14.00% | 1,742.00 | 12.03% | 1,916.00 | 9.99% | 2,069.00 | 7.99% | 2,193.00 | 5.99% |
平均单价(万元) | - | 0.43 | / | 0.39 | 0.39 | 0.39 | -9.62% | 0.40 | 2.92% | 0.41 | 2.50% | 0.42 | 2.44% | 0.42 | 0.00% | 0.43 | 2.38% |
其他病种收入 | - | 271.07 | / | 511.61 | 142.98 | 654.59 | 141.49% | 777.54 | 18.78% | 899.64 | 15.70% | 1,021.83 | 13.58% | 1,140.08 | 11.57% | 1,217.52 | 6.79% |
净利润 | -167.90 | -349.52 | NA | 220.17 | -15.08 | 205.09 | NA | 390.26 | 90.29% | 370.73 | -5.00% | 445.56 | 20.18% | 506.65 | 13.71% | 538.84 | 6.35% |
(27)奥理德视光
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 3,411.31 | 3,941.51 | 15.54% | 3,127.39 | 1,064.94 | 4,192.33 | 6.36% | 5,088.10 | 21.37% | 5,805.30 | 14.10% | 6,551.20 | 12.85% | 7,197.40 | 9.86% | 7,753.20 | 7.72% |
其中:屈光手术 | 73.33 | 120.12 | 63.81% | 124.01 | 23.24 | 147.25 | 22.59% | 232.40 | 57.83% | 315.40 | 35.71% | 390.10 | 23.68% | 456.50 | 17.02% | 498.00 | 9.09% |
手术量次数(次) | 113.00 | 160.00 | 41.59% | 150.00 | 28.00 | 178.00 | 11.25% | 280.00 | 57.30% | 380.00 | 35.71% | 470.00 | 23.68% | 550.00 | 17.02% | 600.00 | 9.09% |
平均单价(万元) | 0.65 | 0.75 | 15.69% | 0.83 | 0.83 | 0.83 | 10.19% | 0.83 | 0.33% | 0.83 | 0.00% | 0.83 | 0.00% | 0.83 | 0.00% | 0.83 | 0.00% |
白内障 | 2,187.17 | 2,254.23 | 3.07% | 1,788.65 | 596.70 | 2,385.35 | 5.82% | 2,585.70 | 8.40% | 2,799.90 | 8.28% | 3,014.10 | 7.65% | 3,213.00 | 6.60% | 3,442.50 | 7.14% |
手术量次数(次) | 1,549.00 | 1,611.00 | 4.00% | 1,172.00 | 390.00 | 1,562.00 | -3.04% | 1,690.00 | 8.19% | 1,830.00 | 8.28% | 1,970.00 | 7.65% | 2,100.00 | 6.60% | 2,250.00 | 7.14% |
平均单价(万元) | 1.41 | 1.40 | -0.90% | 1.53 | 1.53 | 1.53 | 9.14% | 1.53 | 0.19% | 1.53 | 0.00% | 1.53 | 0.00% | 1.53 | 0.00% | 1.53 | 0.00% |
其他病种收入 | 1,150.81 | 1,567.16 | 36.18% | 1,214.73 | 445.00 | 1,659.73 | 5.91% | 2,270.00 | 36.77% | 2,690.00 | 18.50% | 3,147.00 | 16.99% | 3,527.90 | 12.10% | 3,812.70 | 8.07% |
净利润 | 1,173.19 | 1,381.83 | 17.78% | 1,038.41 | 325.71 | 1,364.12 | -1.28% | 1,490.48 | 9.26% | 1,690.15 | 13.40% | 1,921.46 | 13.69% | 2,129.78 | 10.84% | 2,288.84 | 7.47% |
(28)宣城眼科医院
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 3,395.05 | 3,544.19 | 4.39% | 3,049.17 | 1,003.19 | 4,052.36 | 14.34% | 4,529.83 | 11.78% | 5,108.53 | 12.78% | 5,721.48 | 12.00% | 6,408.18 | 12.00% | 7,152.11 | 11.61% |
其中:屈光手术 | 762.79 | 784.92 | 2.90% | 672.78 | 224.10 | 896.88 | 14.26% | 1,009.28 | 12.53% | 1,130.46 | 12.01% | 1,265.75 | 11.97% | 1,417.64 | 12.00% | 1,587.79 | 12.00% |
手术量次数(次) | 800.00 | 872.00 | 9.00% | 806.00 | 270.00 | 1,076.00 | 23.39% | 1,216.00 | 13.01% | 1,362.00 | 12.01% | 1,525.00 | 11.97% | 1,708.00 | 12.00% | 1,913.00 | 12.00% |
平均单价(万元) | 0.95 | 0.90 | -5.26% | 0.83 | 0.83 | 0.83 | -7.39% | 0.83 | -0.42% | 0.83 | 0.00% | 0.83 | 0.00% | 0.83 | 0.00% | 0.83 | 0.00% |
白内障 | 912.92 | 938.86 | 2.84% | 736.81 | 244.20 | 981.01 | 4.49% | 1,102.86 | 12.42% | 1,246.08 | 12.99% | 1,395.90 | 12.02% | 1,563.54 | 12.01% | 1,750.98 | 11.99% |
手术量次数(次) | 1,930.00 | 1,577.00 | -18.29% | 1,109.00 | 370.00 | 1,479.00 | -6.21% | 1,671.00 | 12.98% | 1,888.00 | 12.99% | 2,115.00 | 12.02% | 2,369.00 | 12.01% | 2,653.00 | 11.99% |
平均单价(万元) | 0.47 | 0.60 | 27.66% | 0.66 | 0.66 | 0.66 | 10.55% | 0.66 | -0.50% | 0.66 | 0.00% | 0.66 | 0.00% | 0.66 | 0.00% | 0.66 | 0.00% |
其他病种收入 | 1,719.34 | 1,820.41 | 5.88% | 1,639.58 | 534.89 | 2,174.47 | 19.45% | 2,417.69 | 11.19% | 2,731.99 | 13.00% | 3,059.83 | 12.00% | 3,427.00 | 12.00% | 3,813.34 | 11.27% |
净利润 | 818.61 | 825.90 | 0.89% | 674.84 | 172.09 | 846.93 | 2.55% | 962.48 | 13.64% | 1,117.22 | 16.08% | 1,265.38 | 13.26% | 1,405.72 | 11.09% | 1,570.18 | 11.70% |
(29)万州爱瑞
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 5,382.21 | 5,702.92 | 5.96% | 5,689.00 | 1,352.13 | 7,041.13 | 23.47% | 8,150.85 | 15.76% | 9,199.16 | 12.86% | 10,357.36 | 12.59% | 11,365.76 | 9.74% | 12,471.76 | 9.73% |
其中:屈光手术 | 642.11 | 794.27 | 23.70% | 1,322.07 | 179.40 | 1,501.47 | 89.04% | 1,841.46 | 22.64% | 2,154.48 | 17.00% | 2,508.48 | 16.43% | 2,809.44 | 12.00% | 3,126.69 | 11.29% |
手术量次数(次) | 728.00 | 859.00 | 17.99% | 958.00 | 130.00 | 1,088.00 | 26.66% | 1,306.00 | 20.04% | 1,528.00 | 17.00% | 1,742.00 | 14.01% | 1,951.00 | 12.00% | 2,127.00 | 9.02% |
平均单价(万元) | 0.88 | 0.92 | 4.55% | 1.38 | 1.38 | 1.38 | 50.00% | 1.41 | 2.17% | 1.41 | 0.00% | 1.44 | 2.13% | 1.44 | 0.00% | 1.47 | 2.08% |
白内障 | 2,733.60 | 2,797.54 | 2.34% | 2,616.41 | 743.40 | 3,359.81 | 20.10% | 3,962.88 | 17.95% | 4,517.76 | 14.00% | 5,138.90 | 13.75% | 5,653.05 | 10.01% | 6,256.80 | 10.68% |
手术量次数(次) | 5,360.00 | 5,008.00 | -6.57% | 4,158.00 | 1,180.00 | 5,338.00 | 6.59% | 6,192.00 | 16.00% | 7,059.00 | 14.00% | 7,906.00 | 12.00% | 8,697.00 | 10.01% | 9,480.00 | 9.00% |
平均单价(万元) | 0.51 | 0.56 | 9.80% | 0.63 | 0.63 | 0.63 | 12.40% | 0.64 | 1.68% | 0.64 | 0.00% | 0.65 | 1.56% | 0.65 | 0.00% | 0.66 | 1.54% |
其他病种收入 | 2,006.50 | 2,111.11 | 5.21% | 1,750.52 | 429.33 | 2,179.85 | 3.26% | 2,346.51 | 7.65% | 2,526.92 | 7.69% | 2,709.98 | 7.24% | 2,903.27 | 7.13% | 3,088.27 | 6.37% |
净利润 | 939.57 | 1,074.56 | 14.37% | 1,210.37 | -14.25 | 1,196.12 | 11.31% | 1,349.59 | 12.83% | 1,674.63 | 24.08% | 2,183.95 | 30.41% | 2,534.59 | 16.06% | 2,902.34 | 14.51% |
(30)万州爱瑞-五桥
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,227.49 | 1,335.90 | 8.83% | 917.60 | 307.90 | 1,225.50 | -8.26% | 1,267.87 | 3.46% | 1,332.40 | 5.09% | 1,417.43 | 6.38% | 1,516.67 | 7.00% | 1,657.19 | 9.27% |
其中:屈光手术 | 28.94 | 60.90 | 110.44% | 77.19 | 25.74 | 102.93 | 69.01% | 138.18 | 34.25% | 178.18 | 28.95% | 214.06 | 20.14% | 248.06 | 15.88% | 283.20 | 14.17% |
手术量次数(次) | 34.00 | 66.00 | 94.12% | 54.00 | 18.00 | 72.00 | 9.09% | 94.00 | 30.56% | 118.00 | 25.53% | 139.00 | 17.80% | 158.00 | 13.67% | 177.00 | 12.03% |
平均单价(万元) | 0.85 | 0.92 | 8.24% | 1.43 | 1.43 | 1.43 | 55.39% | 1.47 | 2.83% | 1.51 | 2.72% | 1.54 | 1.99% | 1.57 | 1.95% | 1.60 | 1.91% |
白内障 | 802.37 | 847.97 | 5.68% | 505.62 | 170.10 | 675.72 | -20.31% | 635.04 | -6.02% | 604.94 | -4.74% | 594.60 | -1.71% | 595.82 | 0.21% | 633.60 | 6.34% |
手术量次数(次) | 1,678.00 | 1,718.00 | 2.38% | 945.00 | 315.00 | 1,260.00 | -26.66% | 1,134.00 | -10.00% | 1,043.00 | -8.02% | 991.00 | -4.99% | 961.00 | -3.03% | 990.00 | 3.02% |
平均单价(万元) | 0.48 | 0.49 | 2.08% | 0.54 | 0.54 | 0.54 | 9.45% | 0.56 | 4.42% | 0.58 | 3.57% | 0.60 | 3.45% | 0.62 | 3.33% | 0.64 | 3.23% |
其他病种收入 | 396.18 | 427.03 | 7.79% | 334.79 | 112.06 | 446.85 | 4.64% | 494.65 | 10.70% | 549.28 | 11.04% | 608.77 | 10.83% | 672.79 | 10.52% | 740.39 | 10.05% |
净利润 | 451.59 | 366.04 | -18.94% | 239.30 | 63.88 | 303.18 | -17.17% | 266.08 | -12.24% | 264.97 | -0.42% | 294.43 | 11.12% | 316.83 | 7.61% | 341.71 | 7.85% |
(31)开州爱瑞
单位:万元
项目/年度 | 历史数据 | 预测数据 | |||||||||||||||
2017 | 2018 | 较上年 增长率 | 2019.1-9 | 2019.10- 12 | 2019全年 | 较上年 增长率 | 2020 | 较上年 增长率 | 2021 | 较上年 增长率 | 2022 | 较上年 增长率 | 2023 | 较上年 增长率 | 2024 | 较上年 增长率 | |
营业收入 | 1,724.26 | 1,870.23 | 8.47% | 1,650.11 | 550.33 | 2,200.44 | 17.66% | 2,535.53 | 15.23% | 2,858.40 | 12.73% | 3,174.28 | 11.05% | 3,470.65 | 9.34% | 3,718.10 | 7.13% |
其中:屈光手术 | 53.85 | 113.92 | 111.55% | 161.40 | 53.96 | 215.36 | 89.04% | 260.52 | 20.97% | 299.52 | 14.97% | 335.40 | 11.98% | 373.67 | 11.41% | 403.69 | 8.03% |
手术量次数(次) | 101.00 | 174.00 | 72.28% | 212.00 | 71.00 | 283.00 | 62.64% | 334.00 | 18.02% | 384.00 | 14.97% | 430.00 | 11.98% | 473.00 | 10.00% | 511.00 | 8.03% |
平均单价(万元) | 0.53 | 0.65 | 22.64% | 0.76 | 0.76 | 0.76 | 17.08% | 0.78 | 2.50% | 0.78 | 0.00% | 0.78 | 0.00% | 0.79 | 1.28% | 0.79 | 0.00% |
白内障 | 1,234.11 | 1,223.33 | -0.87% | 1,007.05 | 335.92 | 1,342.97 | 9.78% | 1,478.70 | 10.11% | 1,611.90 | 9.01% | 1,740.20 | 7.96% | 1,860.32 | 6.90% | 1,969.35 | 5.86% |
手术量次数(次) | 2,615.00 | 2,661.00 | 1.76% | 1,937.00 | 646.00 | 2,583.00 | -2.93% | 2,790.00 | 8.01% | 2,985.00 | 6.99% | 3,164.00 | 6.00% | 3,322.00 | 4.99% | 3,455.00 | 4.00% |
平均单价(万元) | 0.47 | 0.46 | -2.13% | 0.52 | 0.52 | 0.52 | 13.03% | 0.53 | 1.94% | 0.54 | 1.89% | 0.55 | 1.85% | 0.56 | 1.82% | 0.57 | 1.79% |
其他病种收入 | 436.30 | 532.98 | 22.16% | 481.66 | 160.45 | 642.11 | 20.48% | 796.31 | 24.01% | 946.98 | 18.92% | 1,098.68 | 16.02% | 1,236.66 | 12.56% | 1,345.06 | 8.77% |
净利润 | 396.74 | 495.57 | 24.91% | 479.32 | 149.74 | 629.06 | 26.94% | 579.48 | -7.88% | 608.85 | 5.07% | 713.74 | 17.23% | 772.21 | 8.19% | 818.51 | 6.00% |
由以上表格可知,评估人员在对各医院分病种收入进行预测时,对主要病种按手术数量、手术单价进行预测,对其他病种按照一定的增长率进行预测,汇总后得到预测营业收入。各标的公司近两年一期的眼科业务快速发展,各病种业务收入、主要病种手术量等实现持续快速增长。本次收益法对各医院的业务收入进行预测时,绝大部分医院预测期内主要病种屈光和白内障的手术量年度增长率最高不超过25%,符合整体行业增长趋势以及医院所在区域的竞争格局;2019年10-12月的手术单价与2019年1-9月的手术单价保持一致,后续年度的手术单价增长率最高不超过5%。从总体上看,各医院预测期营业收入的增长幅度低于近两年一期的增长幅度,且随着医院业务的发展和收入规模的扩张,各医院预测期营业收入的增长幅度逐年走低,详细预测期末(2024年)后维持2024年的收入水平,永续期收入预测不再增长。
标的公司收入增长来源以及可实现性、确定依据及合理性分析如下:
(1)眼科医疗服务行业市场容量不断扩大,需求不断增加
近年来,随着电脑及手机媒体的快速发展,人们用眼强度明显增加,加以人口老龄化因素的影响,我国各类眼病患病率呈上升趋势。随着我国居民眼健康知识的逐步普及,人们的眼保健观念将不断增强,对眼科医疗服务的需求持续增加。与此同时,随着人们收入水平日益提高,我国医疗保障制度不断完善,眼科医疗潜在需求将不断转化为现实的有效需求,大量基本需求将逐步升级为中高端需求。
与此同时,随着人们收入水平日益提高,我国医疗保障制度不断完善,眼科医疗潜在需求将不断转化为现实的有效需求。在需求增加和消费升级的共同作用下,眼科诊疗市场容量不断扩大。2017 年我国眼科市场规模达到 867 亿元,2013年至2017年,我国眼科市场复合年增长率达到16.68%,预计2019年可达到1,117亿元。随着眼科医疗服务需求的进一步提升,眼科医疗服务市场或将继续扩容,行业有望继续保持高景气度发展。
(2)标的医院所处地区人口较多,市场容量较大,且标的医院竞争优势明显
各标的医院主要扎根三、四线城市,该地区人口基数大,但优质眼科医疗服
务资源对比一二线城市较为有限,各医院在当地占据着头部优势地位。随着三四线城市经济高速增长,人们对眼健康的关注日益密切,眼科服务渗透率将不断扩大,各标的医院在当地享有广阔的增长空间。眼科医疗服务行业的持续增长和政策支持下社会办医快速发展为标的医院奠定了良好行业基础, 加上标的医院在当地积累了一定的人才优势,树立了较好的医疗口碑,预测期内业绩能够持续快速增长。
从总体来看,大部分标的医院成立的时间不长,正处于快速发展期,各标的医院2017年到2019年三季度企业营业收入快速增长。随着人们收入水平日益提高以及对眼健康的重视,屈光手术数量将不断增长,屈光手术收入有望大幅提高;白内障(晶状体病)随着焕晶、飞秒白内障等高端手术的推广,手术单价会有所提高,相关营业收入也将不断增长;其他病种收入根据历史经营数据和各地医疗需求发展预计在预测期也将不断保持增长。
综上,标的公司收入增长具有可实现性和合理性,本次评估增值率较高具有合理性。
(二)结合收益法和资产基础法评估结果的差异,详细论述估值差异的原因、披露评估方法的选择依据和评估结果的合理性,并就可能存在的资产减值作风险提示。
1、资产基础法和收益法评估结果差异及原因分析
本次评估天津中视信下属26家医院资产基础法和收益法评估结果差异率介于84.78%至502.64%之间,奥理德视光、宣城眼科医院、开州爱瑞阳光和万州爱瑞阳光4家医院资产基础法和收益法评估结果差异率分别为490.43%、1,401.72%、705.39%和1,845.54%。同时,由于奥理德视光、宣城眼科医院、开州爱瑞和万州爱瑞4家医院在评估基准日前进行了大额的股利分配,因此上述4家医院评估基准日的账面净资产有所减少,从而使得资产基础法的评估结果也相应减少,导致两种方法评估结果的差异率较高。
两种评估方法差异的原因主要是:资产基础法评估是以资产的成本重置为价值标准,反映的是资产投入(购建成本)所耗费的社会必要劳动,这种购建成本通常将随着国民经济的变化而变化;由于上述标的公司的营业场所均为租赁,公
司账面没有房地产等重资产,具有轻资产公司的资产特性,资产基础法评估结果相对较低。而收益法评估是以资产的预期收益为价值标准,反映的是资产的产出能力(获利能力)的大小,这种获利能力通常将受到宏观经济、行业管理以及资产的有效使用等多种条件的影响。在如此两种不同价值标准前提下产生差异是合理的。
2、评估方法的选择依据和评估结果的合理性
收益法是在对企业未来收益预测的基础上评估企业价值的方法,不仅考虑了各分项资产是否在企业中得到合理和充分利用、组合在一起时是否发挥了其应有的贡献等因素对企业股东全部权益价值的影响,也考虑了企业及其所在行业的未来市场发展以及企业所享受的各项优惠政策、医疗资质、行业竞争力、公司的管理水平、医疗队伍人力资源、各种要素协同作用等因素对股东全部权益价值的影响。鉴于本次评估目的为发行股份及支付现金购买资产,交易双方更看重的是被评估企业未来的经营状况和获利能力,收益法更适用于本次评估目的,收益法的评估结果更为合理,因此选用收益法评估结果。
3、对可能存在的资产减值作风险提示
本次发行股份及支付现金购买资产的交易标的为天津中视信100%股权、奥理德视光100%股权、宣城眼科医院80%股权,万州爱瑞90%股权与开州爱瑞90%股权。本次交易采用收益法对标的资产进行评估,截至评估基准日2019年9月30日,天津中视信全部权益的评估值为127,187.09万元,评估增值率4.00%;奥理德视光全部权益的评估值为21,700.07万元,评估增值率607.22%;宣城眼科医院全部权益的评估值为11,625.44万元,评估增值率2,284.46%;万州爱瑞全部权益的评估值为24,240.24万元,评估增值率2,245.43%;开州爱瑞全部权益的评估值为7,760.30万元,增值率873.43%。
本次交易的标的资产评估值较净资产账面价值增值较高,主要是由于标的医院具有较好的持续盈利能力、未来业绩增速较高。由于评估过程的各种假设存在不确定性,存在因未来实际情况与评估假设不一致,特别是宏观经济的波动、产业政策的变化、市场竞争环境改变等情况,使得标的资产未来盈利水平达不到评估时的预测,导致出现标的资产的估值与实际情况不符的情形,进而使得标的资
产出现减值情形。提请投资者注意本次交易存在前述相关因素影响标的资产盈利能力进而影响标的资产估值以及标的资产减值的风险。
(三)评估机构核查意见
经核查,评估机构认为:
1、标的公司收入增长具有可实现性和合理性,本次评估增值率较高具有合理性。
2、本次评估相关标的公司的资产基础法和收益法评估结果的差异是合理的,评估方法的的选择以及评估结果是合理的,公司已对可能存在的资产减值作了相应的风险提示。
湖北众联资产评估有限公司
2020年1月22日